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Background-—The MMP (matrix metalloproteinase) family plays diverse and critical roles in directing vascular wall remodeling in
atherosclerosis. Unlike secreted-type MMPs, a member of the membrane-type MMP family, MT1-MMP (membrane-type 1 MMP;
MMP14), mediates pericellular extracellular matrix degradation that is indispensable for maintaining physiological extracellular
matrix homeostasis. However, given the premature mortality exhibited by MT1-MMP–null mice, the potential role of the proteinase
in atherogenesis remains elusive. We sought to determine the effects of both MT1-MMP heterozygosity and tissue-specific gene
targeting on atherogenesis in APOE (apolipoprotein E)–null mice.
Methods and Results-—MT1-MMP heterozygosity in the APOE-null background (Mmp14+/Apoe/) significantly promoted
atherogenesis relative to Mmp14+/+Apoe/ mice. Furthermore, the tissue-specific deletion of MT1-MMP from vascular smooth
muscle cells (VSMCs) in SM22a-Cre(+)Mmp14F/FApoe/ (VSMC-knockout) mice likewise increased the severity of atheroscle-
rotic lesions. Although VSMC-knockout mice also developed progressive atherosclerotic aneurysms in their iliac arteries,
macrophage- and adipose-specific MT1-MMP–knockout mice did not display this sensitized phenotype. In VSMC-knockout mice,
atherosclerotic lesions were populated by hyperproliferating VSMCs (smooth muscle actin– and Ki67–double-positive cells) that
were characterized by a proinflammatory gene expression profile. Finally, MT1-MMP–null VSMCs cultured in a 3-dimensional
spheroid model system designed to mimic in vivo–like cell–cell and cell–extracellular matrix interactions, likewise displayed
markedly increased proliferative potential.
Conclusions-—MT1-MMP expressed by VSMCs plays a key role in limiting the progression of atherosclerosis in APOE-null mice by
regulating proliferative responses and inhibiting the deterioration of VSMC function in atherogenic vascular walls. ( J Am Heart
Assoc. 2017;6:e003693. DOI: 10.1161/JAHA.116.003693.)
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V ascular smooth muscle cells (VSMCs) constitute themajor cellular component of the tunica media, where
they play key roles in regulating vascular tone and blood
flow.1 Under physiological conditions, the number of VSMCs
within the arterial wall is tightly controlled, as is arterial wall
thickness.1,2 In marked contrast, during the progression of
atherosclerosis, VSMCs proliferate and transition from a
contractile to a synthetic phenotype, thereby depositing
excess extracellular matrix (ECM) molecules that lead to
arterial wall thickening and stiffening, namely, arteriosclero-
sis.3,4 However, the molecular mechanisms that underlie
VSMC proliferation and arteriosclerosis during the patholog-
ical process of atherosclerosis remain largely undefined.
ECM remodeling is mediated by members of the MMP
(matrix metalloproteinase) gene family, a group of structurally
related proteolytic enzymes that are broadly characterized as
either secreted or membrane tethered.5 Consistent with their
potential roles in vascular wall pathology, recent studies have
characterized the roles of secreted MMPs, particularly MMP-
2, MMP-8, and MMP-13, in promoting atherogenesis or plaque
rupture.6–8 With regard to the membrane-tethered MMPs,
MT1-MMP uniquely serves as a pericellular collagenase that
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cleaves native, triple-helical collagens associated with both
the basement membrane and interstitial matrix.9 Indeed, in
contrast to almost all other MMP family members, in which
gene targeting exerts only minor effects on mouse develop-
ment, MT1-MMP–knockout animals display severe dwarfism,
lipodystrophy, and premature lethality, underscoring the key
roles played by MT1-MMP in maintaining tissue homeosta-
sis.10–12 Given the premature lethality of MT1-MMP–knockout
mice, however, attempts to characterize the role of MT1-MMP
in atherogenesis have been limited. Schneider et al used a
bone marrow transplant system to transfer MT1-MMP–null
bone marrow cells into atherogenic Ldlr/ mice to assess
the role of the proteinase when expressed by myeloid cells in
atherogenesis.13 The reconstitution of atherogenic mice with
MT1-MMP–null bone marrow cells did not alter the size of the
atheroma or the number of infiltrating macrophages but did
result in increased collagen content within the atheromatous
lesions.13 Consequently, although myeloid cell–derived MT1-
MMP appears to control collagen turnover, the role of MT1-
MMP in regulating atherogenic responses in non–myeloid cell
populations remains unknown.
Despite the paucity of information regarding the role of
MT1-MMP in atherogenesis, MT1-MMP heterozygous mice,
which do not display any of the severe developmental
phenotypes observed in the MT1-MMP–null mice, have been
reported to display a protected status from both obesity
induced by a high fat diet14 and neointima formation
secondary to carotid injury.15 Given the attenuated responses
of MT1-MMP heterozygous animals to pathologic stresses, we
initially hypothesized that these mice might likewise be
protected from hypercholesterolemic atherogenesis. Contrary
to our expectations, we now report that atherogenesis is
significantly enhanced in heterozygous Mmp14+/Apoe/
mice. To determine the cellular mechanisms by which MT1-
MMP limits the progression of atherogenesis, we extended
our analyses to include newly characterized conditional
knockout mice to selectively target MT1-MMP expression in
adipose tissue, macrophages, or VSMCs in APOE (apolipopro-
tein E)–null mice. Unexpectedly, we found that MT1-MMP
expressed by VSMCs, and not by either adipocytes or
macrophages, exerts a profound protective effect against
the progression of proliferative atherosclerotic lesions in
Apoe/ mice. Together, these results constitute the first
example of MT1-MMP serving as an antiatherogenic enzyme
by directly regulating VSMC function and proliferation in the
in vivo setting.
Material and Methods
Animals
Apoe/ mice16 were purchased from the Jackson Labora-
tory. MT1-MMP heterozygous Mmp14+/ mice were main-
tained on a C57BL6/J background with >5 generations of
backcrossing.14,17 Mmp14+/ mice were crossed to Apoe/
mice to generate Mmp14+/Apoe+/ breeders. Mmp14+/
Apoe+/ mice were used for breeding with Apoe/ mice to
generate Mmp14+/Apoe/ mice and their littermate
Mmp14+/+Apoe/ mice for this study. Mmp14F/F mice were
generated as described previously.18 These mice were
crossed to SM22a-Cre (Tg[Tagln-cre]1Her/J],19 Csf1r-Cre, or
Fabp4-Cre-ERT2 transgenic mice (gift from Pierre Chambon,
Institute of Genetics and Molecular and Cellular Biology,
France),20 and then further crossed to Apoe/ mice.
Atherosclerosis Study
The atherogenic Western diet, composed of 17% (kcal/kcal)
protein, 43% carbohydrate, and 41% fat with 1.5 g/kg
cholesterol, was purchased from Research Diets. Male and
female mice were fed a Western diet for 12 weeks beginning
at 8 weeks of age. All procedures were approved by the
University of Michigan committee on the use and care of
animals, conforming to the guidelines of the International
Association for Assessment and Accreditation of Laboratory
Animal Care.
Morphometric Analysis of Atherosclerosis
After euthanasia by CO2 asphyxiation, blood was collected
through portal veins. Animals were perfused with PBS and
then 10% formalin in PBS through their left ventricles at a rate
Clinical Perspective
What Is New?
• The molecular mechanisms underlying proliferative
atherosclerosis have not been fully defined.
• This animal study suggests that a pericellular collagenase
called MT1-MMP (membrane-type 1 matrix metallopro-
teinase), expressed by vascular smooth muscle cells, plays
a critical role in limiting the progression of proliferative
atherosclerotic lesions.
• The loss of vascular smooth muscle cell MT1-MMP leads to
advanced proliferative atherosclerosis and atherosclerotic
iliac artery aneurysm formation.
What Are the Clinical Implications?
• The functional impairment of vascular smooth muscle cells
in regulating vascular wall extracellular matrix remodeling
may contribute to the pathogenesis of proliferative
atherosclerosis and atherosclerotic iliac artery aneurysm
formation.
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of 1 mL/min, as described previously.21 Arterial trees were
carefully dissected to include the brachiocephalic, left com-
mon carotid, and subclavian arteries, as well as the descend-
ing thoracic and abdominal aortas with the bilateral iliac
arteries. Adipose tissues attached to the arteries were
carefully removed under a dissecting microscope. After Oil
Red O staining and repeated washing in ethanol and water,
aortic trees were pinned against a black background, and the
aortic trees were digitally photographed under a dissecting
microscope.22 Oil Red O–positive areas were quantified as the
percentage of plaque area per total arterial tree or abdominal
aorta.
Collagen Staining and Histologic Analysis
Sections were stained with hematoxylin and eosin and sirius
red.23 The atheroma area and vascular wall area were
quantified in cross-sections using ImageJ software (National
Institutes of Health), and the average plaque and vascular wall
areas were determined. Immunostaining was performed using
the ABC system. The primary antibodies used were rabbit
polyclonal anti–a-smooth muscle actin (anti–a-SMA) antibody,
anti-F4/80 antibody, and anti-Ki67 antibody.
Vascular Smooth Muscle Cells
Mouse aortic smooth muscle cells were isolated with
collagenase digestion, as described by others.24 Isolated
primary mouse VSMCs were cultured in high-glucose DMEM
with 10% FBS and passed twice before experiments. Mouse
primary VSMCs immortalized with the SV40 large T antigen
were purchased from ATCC.25
3-Dimensional Spheroid Culture
Cells (29104) were cultured as hanging droplets in a 384-well
Perfecta3D hanging droplet plate (3D Biomatrix) for 48 hours
before assays.26 Cells were cultured in high-glucose DMEM
with 10% FBS medium supplemented with 0.24% Methocel
A4M (Dow).
Whole-Genome Expression Analysis
The total RNA was extracted from cultured primary VSMCs.
Two independent pairs of samples were used for the DNA
microarray experiments. Labeled cRNA was hybridized to
Affymetrix Mouse Gene ST 2.1 strips at the University of
Michigan DNA Sequencing Core. Expression values were
calculated using a robust multiarray average. Probe sets that
showed >2-fold difference between the groups with a minimal
expression value >24 in at least 1 of the samples were chosen
for further statistical analyses. Data analysis was performed
with R version 3.1.1, and a heat map was created using the
gplots package (R package version 2.17.0, http://CRAN.R-
project.org/package=gplots). Significant biological pathways
represented by the differentially expressed genes were
determined using PANTHER (http://pantherdb.org/).
Statistical Analyses
Values were expressed as meanSEM. The distribution of
weight, fat mass, cholesterol profile, fasting insulin, and
glucose levels between 2 groups were analyzed using a 2-
tailed, unpaired Student t test. To assess the differences in
atherogenesis between the multiple groups, 2-way ANOVA
was used, followed by a post hoc pairwise comparison using
the Tukey procedure. P values <0.05 were considered
significant.
Results
The Effect of the MT1-MMP Gene Dose on Fat
Mass and Dyslipidemia in APOE-Null Mice
We previously demonstrated that MT1-MMP heterozygosity
renders mice resistant to obesity induced by a high fat diet.14
Based on this finding, we hypothesized that the allelic
reduction of the MT1-MMP gene would protect mice from
hypercholesterolemic atherosclerosis, a disease process that
is often associated with obesity in humans.27 As such, we
crossbred MT1-MMP heterozygous (Mmp14+/) mice with
APOE-null mice to generate Mmp14+/Apoe/ mice and
examined the effects of MT1-MMP heterozygosity on weight,
fat mass, blood glucose, and insulin levels as well as
cholesterol profiles. As expected, heterozygous (HT)
Mmp14+/Apoe/ male mice on a Western diet were leaner
than littermate wild-type (WT) Mmp14+/+Apoe/ mice (WT
33.01.0 g, HT 29.00.9 g, n=9 each, P=0.009; Figure 1A).
When fat mass was assessed at the end of the 12-week
Western diet, the total and epididymal fat masses were
significantly smaller in the Mmp14+/Apoe/ than Mmp14+/
+Apoe/ male mice (percentage of total fat mass per weight:
WT 5.10.3%, HT 3.60.6%, n=9 each, P=0.03; percentage of
epididymal fat per weight: WT 3.40.2%, HT 2.20.3%, n=9
each, P=0.007; Figure 1B). Fasting blood glucose levels were
similar between the groups (WT 16243 [n=8] versus HT
16127 mg/dL [n=9], P=0.5); however, the fasting insulin
concentration was substantially lower in the MT1-MMP
heterozygous mice (WT 11.84.3 [n=8] versus HT
3.80.6 mU/L [n=9], P=0.04), suggesting an increased
insulin sensitivity of Mmp14+/Apoe/ mice that occurs in
parallel with their leaner phenotype. Of note, MT1-MMP
heterozygosity did not change the blood cholesterol levels in
APOE-null mice fed a Western diet (total cholesterol: WT
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102159 [n=8] versus HT 101252 mg/dL [n=9], P=0.9;
direct low-density lipoprotein: WT 35927 versus HT
34923 mg/dL, P=0.8; Figure 1C). Consistent with their
leaner phenotype and relative insulin sensitivity, the blood
triglyceride content tended to be lower in HT mice, but this
difference did not reach statistical significance (WT
14210 mg/dL [n=8], HT 11811 mg/dL [n=9], P=0.1).
Whole-Body MT1-MMP Heterozygosity
Accelerates Atherogenesis
MT1-MMP WT and HT mice were fed a Western diet for
12 weeks beginning at 8 weeks of age. Contrary to our
prediction, atherogenesis was more advanced in Mmp14+/
Apoe/ mice compared with Mmp14+/+Apoe/ littermate
controls (Figure 1D). Particularly, advanced atherogenesis
was notable in the abdominal aorta and iliac/femoral arteries
of Mmp14+/Apoe/ mice (Figure 1D arrows). The percent-
age of total plaque area was increased by 21% in male mice
(Mmp14+/+Apoe/ 14.90.9% versus Mmp14+/Apoe/
18.10.8%, n=7 each, P=0.04; Figure 1E, left), whereas the
abdominal percentage of plaque area was increased by 200%
(2.30.5% versus 6.90.5%, n=7 each, P<0.0001; Figure 1E,
right). In female mice, the total plaque area in Mmp14+/
Apoe/ animals was increased by 56% (15.11.3% [n=4]
versus 23.61.6% [n=10], P=0.002; Figure 1F, left), with the
Figure 1. MT1-MMP (membrane-type 1 matrix metalloproteinase) heterozygosity promotes atherosclerosis. A, Mmp14+/+Apoe/ mice and
Mmp14+/Apoe/ mice were fed a Western diet for 12 weeks beginning at 8 weeks of age. Body weight (g) at the end of study. B, Percentage
of fat mass (wt/wt) of total (epididymal plus inguinal) and epididymal fat pads. C, Fasting serum cholesterol (total and direct low-density
lipoprotein) levels. MeanSEM, n=8 and n=10, respectively; *P<0.05. D, Atherosclerotic lesions detected with Oil Red O staining in Mmp14+/
+Apoe/and Mmp14+/Apoe/ male mice. Arrows point to the increased atherogenesis distributed in abdominal aorta and iliac arteries
specifically, as found in Mmp14+/Apoe/ mice. E and F, Oil Red O–positive atherosclerotic plaque areas quantified in all aortic trees and
abdominal aortas in male mice (n=7 each) and female mice (n=4 and n=10). MeanSEM, *P<0.05, **P<0.005, ***P<0.0005. a. indicates
artery.
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abdominal plaque area increasing by 171% relative to the
Mmp14+/+Apoe/ female controls (3.50.2% [n=4] versus
9.51.8% [n=10], P=0.002; Figure 1F, right).
We next examined left carotid artery sections to assess the
structure of the atherosclerotic plaque and the associated
level of vascular wall remodeling. Interestingly, the average
plaque area of the Mmp14+/Apoe/ mice was 3 times as
large as that of the Mmp14+/+Apoe/ mice, but this was not
statistically significant given the variable severity of
atherosclerosis in the heterozygous group (WT
5979103 lm2 versus HT 189849103 lm2, n=6 each,
P=0.15; Figure 2A). Concurrent with a trend of increased
atherosclerosis, we observed a 1.7-fold increase in the
vascular wall area, underscoring the presence of outward
vascular wall remodeling in MT1-MMP heterozygous APOE-
null mice (133169103 lm2 versus 234199103 lm2, n=6
each, P=0.004). Furthermore, both the atherosclerotic
plaques and the vascular walls of MT1-MMP HT mice
displayed an increased collagen fiber content relative to WT
mice, as assessed by sirius red staining (sirius red–positive
area: WT 26.63.3% versus HT 44.04.7%, n=6 each,
P=0.009; Figure 2B), suggesting that MT1-MMP heterozygos-
ity promoted vascular wall arteriosclerosis along with plaque
formation in the APOE-null background. MT1-MMP HT mice
also displayed an apparent loss of a contractile phenotype (ie,
loss of SMA staining) coupled with disrupted elastic lamina,
Figure 2. MT1-MMP (membrane-type 1 matrix metalloproteinase) heterozygosity promotes plaque formation and outward vascular
remodeling. A, Representative histology sections of left common carotid arteries. Hematoxylin and eosin (H&E) and sirius red staining.
Scale=100 lm. B, Sirius red–positive area (%). C, Immunostaining of smooth muscle actin (SMA) in vascular walls and atherosclerotic plaques
(orange). Nuclei were counterstained (blue). Lower panels are of higher magnification. Scale=100 lm. D, SMA-positive area (percentage). Mag
indicates magnification. *P<0.05, **P<0.005
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which in turn elicited more complex and advanced atheroscle-
rotic lesions (Figure 2C and 2D).
MT1-MMP Gene Targeting in VSMCs Accelerates
Atherosclerosis Progression
Although MT1-MMP heterozygosity was found to promote
atherogenesis, the cellular mechanisms underlying the aggra-
vated atherogenesis were unclear. In obesity, perivascular
adipose tissues play a key role in atherogenesis.28 In contrast,
dysfunctional VSMCs might also be responsible for inducing
inflammatory atherogenesis.4 Because MT1-MMP is highly
expressed in both adipocytes9,10 and VSMCs,15 we sought to
use tissue-specific knockout mice in an effort to determine
the cell type responsible for the MT1-MMP–dependent
regulation of atherogenesis. When male mice in each group
were fed a Western diet, we observed markedly augmented
atherogenesis and aneurysm formation only with VSMC-
specific MT1-MMP gene targeting (ie, SM22a-Cre[+]Mmp14F/
FApoe/ mice), but not following adipocyte MT1-MMP gene
targeting (ie, aP2-Cre-ERT2[+]Mmp14F/FApoe/ mice; Fig-
ure 3A). Atherogenesis in SM22a-Cre(+)Mmp14F/FApoe/
Figure 3. Vascular smooth muscle cell MT1-MMP (membrane-type 1 matrix metalloproteinase) gene targeting promotes atherosclerosis and
aneurysm formation. A, Whole arterial trees assessed for Oil Red O–positive atherosclerotic plaque area (red). Arrows point to atherosclerotic
aneurysms. Representative arterial trees from SM22a-Cre()MMP14F/FApoe/ and SM22a-Cre(+)MMP14F/FApoe/ mice are shown; n=13
and n=20, respectively. B, Higher magnification of aortic aneurysms found in SM22a-Cre(+)MMP14F/FApoe/ mice. C, Percentage of plaque
area in Cre()Mmp14F/FApoe/, SM22a-Cre(+)Mmp14F/FApoe/, aP2-Cre-ERT2(+)Mmp14F/FApoe/ mice, males and females (n=8, n=13,
and n=4 in male mice, and n=5, n=7, and n=7 in female mice, respectively). *P<0.05, ***P<0.0005.
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mice frequently extended to femoral arteries with significant
outward remodeling having been noted, in tandem with
aneurysm formation in the iliac arteries (Figure 3A and 3B).
Importantly, total plaque area was increased by 190% in
SM22a-Cre(+)Mmp14F/FApoe/ male mice compared with
Cre()Mmp14F/FApoe/ male mice (8.01.4% [n=8] versus
23.51.4% [n=13], P<0.0001) and 210% in female mice
(4.90.9% [n=5] versus 15.53.5% [n=7], P=0.03). In con-
trast, significant differences were not observed between Cre-
negative controls and the adipose-specific MT1-MMP deletion
model (Figure 3C and Figure S1), suggesting that the VSMCs
are the primary cell type that mediates MT1-MMP–dependent
modulation of atherogenesis progression.
The Loss of VSMC MT1-MMP Leads to
Proliferative Atherosclerotic Lesions and
Aneurysm Formation
After 12-week Western diet feeding, SM22a-Cre(+)
Mmp14F/FApoe/ mice developed extensive atheroscle-
rosis in their common iliac arteries followed by aneurysm
formation (Figure 4A and 4B). No aneurysm formation was
observed in the Cre()Mmp14F/FApoe/ mice (8 male
and 5 female mice), whereas 11 of 12 male and 6 of 7
female SM22a-Cre(+)Mmp14F/FApoe/ mice developed
strikingly enlarged aneurysms that were readily observ-
able on dissection (Figure 3B). These dysmorphic lesions
displayed significant vascular wall thickening as well as
atheroma formation (Figure 4A). Masson’s Trichrome and
Verhoeff–Van Gieson staining demonstrated the disruption
and loss of elastic laminae (Figure 4A). SMA staining
showed an increased number of SMA+ cells in vascular
walls as well as within atheroma, where Ki67 staining
confirmed that large numbers of SMA+ cells existed in a
proliferative state (Figure 4A and 4D). Infiltration of F4/
80-positive cells was observed in the atheroma and the
vascular walls of affected vessels (Figure 4A, F4/80
staining) but to a lesser extent compared with VSMCs.
Image quantification of the lesions confirmed an
increased atheroma area (Figure 4B) and outward remod-
eling (Figure 4C), which were coupled with an increased
number of proliferating VSMCs (Figure 4D). Because
macrophages are potentially targeted by SM22a pro-
moter-driven Cre expression,29 we specifically targeted
these cells using Csf1r-Cre(+)Mmp14F/FApoe/ mice and
examined atherosclerosis and aneurysm formation. Nei-
ther littermate control Csf1r-Cre()Mmp14F/FApoe/
mice nor Csf1r-Cre(+)Mmp14F/FApoe/ mice developed
atherosclerotic iliac aneurysm after 12 weeks of Western
diet (n=7 for each group tested), and no significant
differences in the sizes of atherosclerosis lesions were
observed (n=4 each).
Proinflammatory and Metabolically Dysfunctional
MT1-MMP–Null VSMCs
To assess the role of MT1-MMP in VSMC function, we isolated
primary VSMCs from descending aortas. As expected, VSMCs
isolated from SM22-Cre(+)Mmp14F/FApoe/ mice demon-
strated specific Cre expression along with the suppression
MT1-MMP gene expression (Figure S2). In vitro, MT1-MMP–
null VSMCs displayed a flattened, spread shape with higher
stress fiber formation (Figure 5A), whereas the expression of
other MMPs (eg, MMP-2, MMP-8, MMP-9, MMP-13, and MT2-
MMP [MMP15]), were not significantly different between
control and MT1-MMP–deleted cells (Figure S2). The Acta2
gene, which encodes a-SMA, was expressed equally in primary
VSMCs isolated from SM22-Cre()Mmp14F/FApoe/ and
SM22-Cre(+)Mmp14F/FApoe/ mice (Figure S2). To gain
further insight into the effects of MT1-MMP gene targeting in
VSMCs, whole-genome transcriptome analysis was performed.
Using a minimum 2-fold difference as a cutoff, 414 genes were
found to be differentially expressed between the 2 groups (the
top 70 genes are shown in Figure 5B, and all differentially
expressed genes are listed in Table S1; the microarray data is
available at NCBI Gene Expression Omnibus [GSE] as
GSE100661). Interestingly, the genes upregulated in SM22a-
Cre(+)Mmp14F/FApoe/ VSMCs (>2.3-fold change) were
aggregated in the pathways of inflammation and cell killing
(Figure 5C), suggesting the acquisition of a proinflammatory
phenotype in MT1-MMP–null VSMCs.
MT1-MMP Gene Targeting Promotes VSMC
Proliferation in 3-Dimensional Cell–Cell and Cell–
ECM Contexts
To gain insights into the mechanism by which MT1-MMP–
null VSMCs engage in the formation of proliferative
atherosclerotic lesions, we developed an in vivo–like 3-
dimensional (3-D) spheroid culture system in which in vivo–
like cell–cell and cell–ECM interactions could be recapitu-
lated. Using Ki67 as an index of proliferative responses,
MT1-MMP–null primary VSMCs displayed markedly higher
activity relative to WT cells (Figure 6A and 6B). To determine
whether the observed differences in cell proliferation were a
direct consequence of MT1-MMP gene targeting (ie, as
opposed to a secondary response of VSMCs recovered from
the advanced atherogenic lesions found in VSMC-knockout
mice), we used immortalized mouse primary VSMCs to
further define the role of MT1-MMP in regulating VSMC
proliferation. In 3-D spheroid culture, similar to the findings
obtained with freshly isolated VSMCs, small interfering RNA–
mediated MT1-MMP gene silencing in mouse VSMCs
induced a marked increase in the number of Ki67-positive
VSMCs (Figure 6C and 6D). Of note, under 2-D culture
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conditions, MT1-MMP silencing exerted minimal effects on
mouse VSMC proliferation (Figure 6E and 6F). Taken
together, these results support a model in which MT1-
MMP plays a required role in regulating VSMC proliferative
activity but only under 3-D conditions that more closely
recapitulate the in vivo environment.
Figure 4. The loss of vascular wall integrity and vascular smooth muscle cell (VSMC) proliferation in VSMC MT1-MMP (membrane-type 1
matrix metalloproteinase) knockout mice. A, Atherosclerotic aneurysms found in iliac arteries of SM22a-Cre(+)MMP14F/FApoe/ mice.
Masson’s Trichrome staining; the border between the vascular wall and the atheroma is demarcated with a dashed line. Verhoeff–Van Gieson
staining (VVG), smooth muscle actin (SMA) staining, Ki67 staining, and F4/80 (a macrophage marker) staining. Scale=100 lm. The lower
magnification (94) micrograph of SM22a-Cre(+)MMP14F/FApoe/ VVG staining on the right. Scale=200 lm. The lesion in the dashed square
is shown on the left. B, Plaque area. C, The internal diameter of iliac arteries. D, Ki67-positive area. MeanSEM; n=5 and n=7 for each group.
One-way ANOVA. *P<0.05, **P<0.005.
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Discussion
MMP family members play a key role in ECM turnover in a
wide variety of developmental and disease processes.30
Among the collagen-degrading MMPs, secreted (MMP-3,
MMP-8, MMP-13) and membrane-type MMPs (MT1- and
MT2-MMP) display distinct temporospatial differences in their
patterns of expression and activity.9 Unlike other MMPs, MT1-
MMP (MMP14) is the only family member whose activity is
indispensable for postnatal development.10,11 Because of the
premature morbidity and mortality displayed by MT1-MMP–
null mice, the role of the proteinase in cardiovascular disease
has remained elusive. To date, the only MT1-MMP–expressing
cellular compartment tested in a mouse atherogenesis model
was bone marrow–derived myeloid cells; however, no sub-
stantial impact on atheroma size was observed following bone
marrow reconstitution with Mmp14/ cells.13 In our study,
we identified the critical role played by VSMC-derived MT1-
MMP in regulating the progression of atherosclerotic lesions
and the associated formation of vascular aneurysms.
Previously, we demonstrated that MT1-MMP heterozygos-
ity protects C57BL/6 mice from diet-induced adipose tissue
expansion.14 Similarly, in this study, heterozygous Mmp14+/
mice displayed a leaner phenotype relative to Mmp14+/+ mice
in an APOE-null background. Consistent with their leaner
phenotype, MT1-MMP heterozygous mice displayed higher
insulin sensitivity than WT mice. Given the metabolically
improved status of Mmp14+/ mice, we initially hypothesized
that MT1-MMP heterozygosity would protect mice from
hypercholesterolemic atherosclerosis, which is often associ-
ated with increased adiposity. Contrary to our expectations,
MT1-MMP heterozygous APOE-null mice developed more
extensive atherosclerotic lesions than MT1-MMP–sufficient
APOE-null mice, suggesting a potentially beneficial role for
MT1-MMP in limiting disease progression. The results also
Figure 5. Proinflammatory gene expression in MT1-MMP (membrane-type 1 matrix metalloproteinase)–null vascular smooth muscle cells
(VSMCs). A, Primary aortic VSMCs isolated from Cre()Mmp14F/FApoe/ and SM22a-Cre(+)/Mmp14F/FApoe/ mice. F-actin (green), nuclei
(blue). B, Representative genes differentially expressed in VSMCs from 2 independent pairs of Cre()Mmp14F/FApoe/ and SM22a-Cre(+)/
Mmp14F/FApoe/ mice. C, Gene Ontology (GO) biological processes represented by the genes upregulated in VSMCs isolated from the
SM22a-Cre(+)/Mmp14F/FApoe/ mice.
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Figure 6. MT1-MMP (membrane-type 1 matrix metalloproteinase) limits vascular smooth muscle cell
(VSMC) proliferation in 3-dimensional (3-D) organoids. A, Primary VSMCs isolated from Cre()
Mmp14F/FApoe/ mice and Cre(+)Mmp14F/FApoe/ mice were cultured as a 3-D spheroids for 48 hours
and stained for Ki67 (red), nuclei (DAPI, blue), and actin (phalloidin, green). B, Quantified intensity of Ki67
staining per spheroid. n=5 to 7. *P<0.05. C, Immortalized mouse VSMCs (MOVAS) transiently transfected
with small interfering RNA (siRNA) control (siControl) and MT1-MMP siRNA (siMmp14). Ki67 (red), nuclei
(blue), actin (green). D, Ki67 staining intensity per spheroid of MOVAS. **P<0.005. E, 2-D cultured MOVAS
transfected with control and MT1-MMP siRNA. Ki67 (red), nucleus (blue), and actin (green). F, Ki67-positive
nuclei per total nuclei count.
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suggest that the inverse relationship observed between fat
mass and atherosclerosis—the so-called obesity paradox in
humans—may reflect the independent biological effects
exerted by a cohort of modifier genes, including MT1-MMP,
on adipose tissue and vascular function.
To define the cellular mechanisms by which MT1-MMP
exerts its antiatherogenic effects, we embarked on a series of
studies aimed at tissue-specific MT1-MMP gene targeting in
APOE-null mice. In the early stages of our efforts, we focused
on 2 cell types: adipocytes and VSMCs. We initially hypoth-
esized that the loss of adipocyte MT1-MMP would modify
atherogenesis via the potentially causal links that exist
between adipose tissue and the vascular wall.31 In APOE-
null mice, however, we were unable to observe a significant
impact on atherogenesis following gene targeting of adipo-
cyte-derived MT1-MMP. In contrast, the SM22a-Cre-mediated
loss of VSMC MT1-MMP strikingly aggravated atherosclerosis
progression in APOE-null mice. Whole-genome transcriptome
analyses indicated that a series of proinflammatory genes
were upregulated in MT1-MMP–null VSMCs, a finding consis-
tent with the proatherogenic phenotype of SM22a-Cre(+)
Mmp14F/FApoe/ mice. Furthermore, our in vitro studies
demonstrated that MT1-MMP targeting in either primary or
immortalized VSMCs promotes cell proliferation under 3-D
spheroid culture conditions.26 As such, 3-D spheroid culture
appears to reflect a set of conditions that better reflect our
in vivo findings and, as such, can be used to more faithfully
address cellular behavior in tissue-like contexts by re-creating
cell–cell and cell–ECM interactions ex vivo. Indeed, previous
work has demonstrated that VSMC proliferative activity can
be regulated by cell–cell adhesion32–34 and cell–ECM inter-
actions.35,36 Of note, the enhanced proliferative responses
displayed by MT1-MMP–null VSMCs were not observed under
conventional 2-D culture conditions in which the cell–cell and
cell–ECM interactions that are encountered in vivo are
replaced by cell culture atop a nonphysiologic, planar, and
rigid substratum. Finally, it is interesting to note that the
proliferative effects of MT1-MMP gene silencing were not
observed in other cell types, for example, 3T3-L1 preadipo-
cytes (data not shown), reinforcing the unique role played by
MT1-MMP in VSMC biology.
In considering the mechanisms by which MT1-MMP might
control proliferative activity, efforts are complicated by the
proteinase’s broad substrate repertoire, ranging from type I
collagen37 to CD4438 and cadherins.39 As such, MT1-MMP
can potentially regulate VSMC proliferation by degrading any
number of membrane-associated protein targets as well as
pericellular ECM molecules, thereby modifying both cell–cell
adhesion and cell–ECM interaction. In atherosclerosis, the
expression of adhesion molecules and ECM proteins is highly
upregulated40; as such, a decrease in MT1-MMP activity
would be predicted to trigger the excess accumulation of ECM
macromolecules as well as cell-surface adhesion molecules.
At this juncture, we posit that changes in the dynamics of
ECM turnover and cell-surface molecule expression occurring
within the vascular wall lead to the unregulated proliferation
of VSMCs and the development of a proinflammatory pheno-
type. Interestingly, at least in terms of proliferative responses,
the use of a 3-D spheroid model allowed us to recapitulate the
MT1-MMP–dependent biological processes ex vivo. Neverthe-
less, it remains unclear how the cleavage of MT1-MMP
substrate(s) accelerates VSMC proliferation in APOE-null mice.
This caveat notwithstanding, our data clearly highlight the role
played by VSMC-derived MT1-MMP in limiting the progression
of proliferative atherosclerotic lesions. Because MT1-MMP is a
membrane-bound proteinase, the physical proximity of sub-
strates with the enzyme is likely critical for the protective
effects exerted by VSMCs in limiting the expansion of
atherosclerotic lesions. Our study also suggests that other
atherosclerosis-associated MMPs (eg, MMP-2, MMP-8,
MMP-13) do not compensate for the genetic loss of MT1-
MMP and are unable to limit atherosclerosis progression.
Although MT2-MMP (MMP15) was also expressed in mouse
VSMCs (Figure S2), as reported previously in rat VSMCs,41 the
biological phenotypes conferred by MT1-MMP gene loss were
not rescued by the presence of MT2-MMP. Differences in the
hemopexin domain structure, posttranslational modification,
or protein trafficking may underlie the specific effects
mediated by MT1-MMP versus MT2-MMP.42
Although increased collagen content within atheroma
might be predicted to play a protective role against plaque
rupture, collagen accumulation in arterial walls could also
accentuate vascular sclerosis and stiffening. In turn, stiff and
sclerotic blood vessels could increase luminal sheer stress,
thereby increasing the chance of plaque rupture. In future
studies, an assessment of hemodynamic changes and plaque
instability in our model will be required to more accurately
define the role of MT1-MMP in cardiovascular disease.
Interestingly, in APOE-null mice, arterial wall stiffness is
known to be increased through VSMC lysyl oxidase activity.43
In turn, increased tissue stiffness could control VSMC
proliferation through the activation of a mechanotransduction
pathway, for example, YAP/TAZ transcription activity.44 As
such, we posit that the pathologic accumulation of ECM
macromolecules secondary to the loss of MT1-MMP activity
may further promote vascular wall rigidity in the APOE-null
mice, leading to hyperproliferative vascular lesions and
aneurysm formation. Given that we observed severe
atherosclerosis and aneurysm formation in iliac and femoral
arteries, site-specific increases in vascular wall thickening and
arteriosclerosis are likely related to the distinct mechanical
properties of vessel walls observed along the arterial tree.45
Indeed, femoral arteries as well as the abdominal aorta are
known to display higher wall thickness with lower content of
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elastic lamina compared with carotid arteries and thoracic
aortas.45 Together, differences in mechanical stress and ECM
composition may render VSMCs in abdominal aortae and
femoral arteries more vulnerable to atherogenic proliferation.
Finally, it remains to be determined whether the inflamma-
tory gene expression profile observed in MT1-MMP–null
VSMCs is restricted to atherogenic milieu encountered
in vivo. Interestingly, in our hands, the increase in inflammatory
gene expression of MT1-MMP–null VSMCs was coupled with
decreased mitochondrial activity (T. Akama, PhD, unpublished
data, 2016). Furthermore, recent studies have demonstrated a
critical role played by a VSMC phenotypic switch to macro-
phage-like cells in atherogenesis.4,46 Because MT1-MMP also
regulates inflammatory responses in macrophages,47 the
proteinase may well play a key role in controlling a complex
set of metabolic and phenotypic switching programs that are
engaged in atherogenic VSMCs. Although further work is
needed to delineate MT1-MMP function during atherogenesis,
our work highlights the previously unsuspected vessel wall–
protective effects exerted by this membrane-anchored metal-
loproteinase in the VSMC compartment.
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Table S1. List of genes differentially expressed in Cre(-) and SM22α-Cre(+)Mmp14F/F VSMCs 
 
ENTREZ ID SYMBOL GENE NAME 
Cre(-) 
1 
Cre(-) 
2 
Cre(+) 
1 
Cre(+) 
2 
Cre(-) 
AVG 
Cre(+) 
AVG 
Log2 
(pos-
nega) 
Fold- 
change 
379043 Raet1e retinoic acid early transcript 1E 3.4 3.2 5.6 6.7 3.3 6.2 2.8 7.1 
57266 Cxcl14 
chemokine (C-X-C motif) ligand 
14 5.4 4.7 8.6 6.4 5.0 7.5 2.5 5.7 
20210 Saa3 serum amyloid A 3 3.4 6.0 7.3 7.0 4.7 7.1 2.5 5.5 
14941 Gzmd granzyme D 2.0 2.2 6.8 2.1 2.1 4.4 2.4 5.1 
57781 Cd200r1 CD200 receptor 1 4.1 3.8 6.0 6.5 3.9 6.3 2.4 5.1 
17533 Mrc1 mannose receptor, C type 1 4.9 5.7 7.0 7.7 5.3 7.4 2.1 4.2 
80891 Fcrls 
Fc receptor-like S, scavenger 
receptor 6.0 3.7 8.2 5.6 4.8 6.9 2.1 4.2 
232413 Clec12a 
C-type lectin domain family 12, 
member a 4.8 5.3 7.3 6.8 5.0 7.0 2.0 4.1 
56744 Pf4 platelet factor 4 4.3 5.2 5.5 8.1 4.8 6.8 2.0 4.1 
21810 Tgfbi 
transforming growth factor, 
beta induced 6.0 6.7 8.2 8.5 6.3 8.3 2.0 4.0 
72318 Cyth4 cytohesin 4 5.8 5.7 7.6 7.9 5.8 7.7 2.0 3.9 
15951 Ifi204 interferon activated gene 204 3.2 4.3 6.1 5.3 3.8 5.7 2.0 3.9 
320292 Rasgef1b 
RasGEF domain family, member 
1B 3.7 3.9 5.8 5.7 3.8 5.8 2.0 3.9 
12774 Ccr5 
chemokine (C-C motif) receptor 
5 3.4 3.0 4.8 5.4 3.2 5.1 1.9 3.7 
14276 Folr2 folate receptor 2 (fetal) 5.0 4.5 8.0 5.4 4.8 6.7 1.9 3.7 
20556 Slfn2 schlafen 2 6.2 5.9 7.9 8.0 6.0 7.9 1.9 3.7 
15109 Hal histidine ammonia lyase 2.4 2.8 2.5 6.5 2.6 4.5 1.9 3.7 
243277 Gpr133 G protein-coupled receptor 133 2.9 4.1 6.1 4.7 3.5 5.4 1.9 3.6 
68774 Ms4a6d 
membrane-spanning 4-
domains, subfamily A, member 
6D 5.7 5.6 7.5 7.5 5.6 7.5 1.8 3.6 
17916 Myo1f myosin IF 5.6 5.7 7.3 7.7 5.7 7.5 1.8 3.6 
107321 Lpxn leupaxin 3.2 3.7 5.5 5.0 3.4 5.2 1.8 3.5 
246177 Myo1g myosin IG 3.3 3.3 4.4 5.8 3.3 5.1 1.8 3.5 
20452 St8sia4 
ST8 alpha-N-acetyl-
neuraminide alpha-2,8-
sialyltransferase 4 4.0 4.5 5.7 6.3 4.3 6.0 1.8 3.4 
109648 Npy neuropeptide Y 8.0 7.5 8.9 10.1 7.7 9.5 1.8 3.4 
17084 Ly86 lymphocyte antigen 86 4.3 5.5 6.2 7.0 4.9 6.6 1.8 3.4 
19264 Ptprc 
protein tyrosine phosphatase, 
receptor type, C 6.6 6.7 8.3 8.5 6.6 8.4 1.8 3.4 
13733 Emr1 
EGF-like module containing, 
mucin-like, hormone receptor-
like sequence 1 6.1 6.0 7.9 7.6 6.0 7.8 1.7 3.3 
14727 Gp49a glycoprotein 49 A 6.6 5.9 7.8 8.2 6.3 8.0 1.7 3.3 
23845 Clec5a 
C-type lectin domain family 5, 
member a 4.4 4.7 5.8 6.8 4.6 6.3 1.7 3.3 
20568 Slpi 
secretory leukocyte peptidase 
inhibitor 5.0 4.7 6.2 6.9 4.9 6.6 1.7 3.3 
20308 Ccl9 chemokine (C-C motif) ligand 9 5.2 6.0 6.9 7.7 5.6 7.3 1.7 3.2 
18733 Pirb paired Ig-like receptor B 5.5 5.9 7.1 7.7 5.7 7.4 1.7 3.2 
17060 Blnk B cell linker 6.1 6.1 7.8 7.8 6.1 7.8 1.7 3.2 
100303646 AF357355 snoRNA AF357355 3.2 3.2 6.1 3.6 3.2 4.9 1.7 3.2 
20288 Msr1 
macrophage scavenger 
receptor 1 6.4 6.7 8.1 8.4 6.6 8.2 1.7 3.2 
66109 Tspan13 tetraspanin 13 4.0 5.3 6.4 6.2 4.6 6.3 1.7 3.2 
11501 Adam8 
a disintegrin and 
metallopeptidase domain 8 6.6 6.5 8.3 8.0 6.5 8.2 1.7 3.1 
319446 Dpep2 dipeptidase 2 5.3 3.9 6.6 5.9 4.6 6.3 1.7 3.1 
544963 Iqgap2 
IQ motif containing GTPase 
activating protein 2 5.4 4.9 6.3 7.3 5.2 6.8 1.6 3.1 
69769 Tnfaip8l2 
tumor necrosis factor, alpha-
induced protein 8-like 2 4.6 4.9 6.1 6.8 4.8 6.4 1.6 3.1 
12506 Cd48 CD48 antigen 5.8 5.3 6.9 7.5 5.6 7.2 1.6 3.1 
382062 AB124611 cDNA sequence AB124611 5.1 5.1 6.3 7.1 5.1 6.7 1.6 3.1 
15900 Irf8 interferon regulatory factor 8 5.5 5.2 6.6 7.3 5.4 7.0 1.6 3.1 
20299 Ccl22 chemokine (C-C motif) ligand 22 2.7 3.3 2.6 6.7 3.0 4.6 1.6 3.0 
20345 Selplg 
selectin, platelet (p-selectin) 
ligand 5.5 5.1 6.3 7.5 5.3 6.9 1.6 3.0 
22324 Vav1 vav 1 oncogene 4.5 3.8 5.6 5.9 4.2 5.8 1.6 3.0 
16592 Fabp5 
fatty acid binding protein 5, 
epidermal 8.5 8.0 9.4 10.2 8.2 9.8 1.6 3.0 
17476 Mpeg1 macrophage expressed gene 1 6.9 6.6 8.0 8.7 6.8 8.3 1.6 3.0 
233571 P2ry6 
pyrimidinergic receptor P2Y, G-
protein coupled, 6 6.9 6.6 8.5 8.2 6.7 8.3 1.6 3.0 
15170 Ptpn6 
protein tyrosine phosphatase, 
non-receptor type 6 5.0 5.3 6.4 7.1 5.2 6.7 1.6 3.0 
83433 Trem2 
triggering receptor expressed 
on myeloid cells 2 7.4 7.0 8.6 9.0 7.2 8.8 1.6 3.0 
11690 Alox5ap 
arachidonate 5-lipoxygenase 
activating protein 7.7 7.4 9.1 9.1 7.6 9.1 1.6 2.9 
12259 C1qa 
complement component 1, q 
subcomponent, alpha 
polypeptide 6.6 6.9 8.2 8.4 6.7 8.3 1.6 2.9 
20302 Ccl3 chemokine (C-C motif) ligand 3 6.4 7.1 7.7 9.0 6.8 8.3 1.6 2.9 
16912 Psmb9 
proteasome (prosome, 
macropain) subunit, beta type 9 
(large multifunctional peptidase 
2) 4.6 4.8 5.8 6.7 4.7 6.3 1.6 2.9 
14131 Fcgr3 Fc receptor, IgG, low affinity III 6.3 6.7 7.8 8.3 6.5 8.1 1.5 2.9 
12768 Ccr1 
chemokine (C-C motif) receptor 
1 3.3 3.4 4.0 5.7 3.3 4.9 1.5 2.9 
16149 Cd74 
CD74 antigen (invariant 
polypeptide of major 
histocompatibility complex, 
class II antigen-associated) 3.9 3.4 3.7 6.6 3.6 5.1 1.5 2.9 
17970 Ncf2 neutrophil cytosolic factor 2 5.2 5.6 6.5 7.4 5.4 7.0 1.5 2.9 
17972 Ncf4 neutrophil cytosolic factor 4 3.6 4.3 5.2 5.8 4.0 5.5 1.5 2.9 
14129 Fcgr1 Fc receptor, IgG, high affinity I 4.6 4.6 6.4 5.8 4.6 6.1 1.5 2.9 
74272 1700054O19Rik RIKEN cDNA 1700054O19 gene 2.5 4.0 4.8 4.7 3.2 4.7 1.5 2.8 
12767 Cxcr4 
chemokine (C-X-C motif) 
receptor 4 6.8 6.6 8.1 8.3 6.7 8.2 1.5 2.8 
23900 Hcst 
hematopoietic cell signal 
transducer 5.1 5.7 6.2 7.6 5.4 6.9 1.5 2.8 
54712 Plxnc1 plexin C1 6.5 5.6 7.4 7.7 6.0 7.5 1.5 2.8 
19354 Rac2 
RAS-related C3 botulinum 
substrate 2 6.9 6.9 8.1 8.7 6.9 8.4 1.5 2.8 
668218 Bin2 bridging integrator 2 3.0 2.9 3.9 5.0 2.9 4.4 1.5 2.8 
217305 Cd300ld 
CD300 molecule-like family 
member d 4.8 5.2 6.2 6.7 5.0 6.5 1.5 2.8 
12984 Csf2rb2 
colony stimulating factor 2 
receptor, beta 2, low-affinity 
(granulocyte-macrophage) 6.3 6.0 7.3 8.0 6.1 7.6 1.5 2.8 
13618 Ednrb endothelin receptor type B 4.4 4.3 5.2 6.4 4.3 5.8 1.5 2.8 
14130 Fcgr2b Fc receptor, IgG, low affinity IIb 5.4 5.4 6.4 7.5 5.4 6.9 1.5 2.8 
14544 Gda guanine deaminase 4.8 5.9 6.3 7.4 5.4 6.8 1.5 2.8 
14744 Gpr65 G-protein coupled receptor 65 5.8 4.9 7.1 6.7 5.4 6.9 1.5 2.8 
66857 Plbd1 
phospholipase B domain 
containing 1 3.2 4.9 3.2 7.8 4.0 5.5 1.5 2.8 
16534 Kcnn4 
potassium intermediate/small 
conductance calcium-activated 
channel, subfamily N, member 
4 4.0 4.3 5.8 5.5 4.2 5.7 1.5 2.8 
320207 Pik3r5 
phosphoinositide-3-kinase, 
regulatory subunit 5, p101 5.9 5.7 7.2 7.4 5.8 7.3 1.5 2.8 
216869 Arrb2 arrestin, beta 2 5.5 5.5 6.8 7.1 5.5 7.0 1.5 2.8 
19735 Rgs2 
regulator of G-protein signaling 
2 5.3 4.4 6.2 6.5 4.9 6.3 1.5 2.8 
217203 Tmem106a transmembrane protein 106A 6.9 6.8 8.4 8.2 6.8 8.3 1.5 2.8 
215632 Psd4 
pleckstrin and Sec7 domain 
containing 4 4.1 2.9 4.7 5.1 3.5 4.9 1.5 2.7 
226652 Arhgap30 
Rho GTPase activating protein 
30 4.8 4.6 5.8 6.4 4.7 6.1 1.4 2.7 
12047 Bcl2a1d 
B cell leukemia/lymphoma 2 
related protein A1d 7.6 7.5 8.9 9.1 7.5 9.0 1.4 2.7 
76933 Ifi27l2a 
interferon, alpha-inducible 
protein 27 like 2A 3.5 3.4 5.4 4.4 3.5 4.9 1.4 2.7 
16197 Il7r interleukin 7 receptor 6.7 7.2 7.8 9.0 7.0 8.4 1.4 2.7 
17085 Ly9 lymphocyte antigen 9 4.1 4.3 5.2 6.1 4.2 5.7 1.4 2.7 
105855 Nckap1l NCK associated protein 1 like 6.9 6.8 8.2 8.4 6.8 8.3 1.4 2.7 
239849 Cd200r4 CD200 receptor 4 6.6 6.2 7.7 8.0 6.4 7.9 1.4 2.7 
16409 Itgam integrin alpha M 5.7 5.9 6.4 8.0 5.8 7.2 1.4 2.7 
50934 Slc7a8 
solute carrier family 7 (cationic 
amino acid transporter, y+ 
system), member 8 5.9 5.8 7.2 7.4 5.9 7.3 1.4 2.7 
107769 Tm6sf1 
transmembrane 6 superfamily 
member 1 5.4 5.5 6.6 7.2 5.5 6.9 1.4 2.7 
94176 Dock2 dedicator of cyto-kinesis 2 4.4 4.6 5.7 6.1 4.5 5.9 1.4 2.7 
223433 Fam105a 
family with sequence similarity 
105, member A 5.1 5.0 6.1 6.8 5.1 6.5 1.4 2.7 
279572 Tlr13 toll-like receptor 13 6.6 6.2 7.5 8.1 6.4 7.8 1.4 2.7 
54486 Hpgds 
hematopoietic prostaglandin D 
synthase 5.0 4.9 6.3 6.4 4.9 6.3 1.4 2.6 
15559 Htr2b 
5-hydroxytryptamine 
(serotonin) receptor 2B 3.8 4.2 5.3 5.6 4.0 5.4 1.4 2.6 
11810 Apobec1 
apolipoprotein B mRNA editing 
enzyme, catalytic polypeptide 1 7.3 7.4 8.8 8.7 7.3 8.7 1.4 2.6 
17079 Cd180 CD180 antigen 6.9 6.7 8.3 8.0 6.8 8.2 1.4 2.6 
13723 Emb embigin 7.0 6.9 7.9 8.8 7.0 8.3 1.4 2.6 
67092 Gatm 
glycine amidinotransferase (L-
arginine:glycine 
amidinotransferase) 4.8 4.9 5.7 6.8 4.9 6.2 1.4 2.6 
382301 Sly Sycp3 like Y-linked 4.4 4.9 6.3 5.9 4.7 6.1 1.4 2.6 
27052 Aoah acyloxyacyl hydrolase 3.4 3.2 4.4 5.0 3.3 4.7 1.4 2.6 
20304 Ccl5 chemokine (C-C motif) ligand 5 4.7 5.3 5.1 7.6 5.0 6.4 1.4 2.6 
12475 Cd14 CD14 antigen 5.6 5.8 7.1 7.0 5.7 7.1 1.4 2.6 
246177 Myo1g myosin IG 4.3 4.0 5.1 6.0 4.1 5.5 1.4 2.6 
17969 Ncf1 neutrophil cytosolic factor 1 5.1 4.5 5.9 6.5 4.8 6.2 1.4 2.6 
14960 H2-Aa 
histocompatibility 2, class II 
antigen A, alpha 2.8 2.7 2.6 5.6 2.8 4.1 1.4 2.6 
98496 Pid1 
phosphotyrosine interaction 
domain containing 1 4.4 4.3 6.1 5.3 4.3 5.7 1.4 2.6 
140497 AF251705 cDNA sequence AF251705 6.2 6.0 7.1 7.9 6.1 7.5 1.4 2.6 
387142 Mir24-1 microRNA 24-1 3.3 4.0 5.6 4.5 3.7 5.0 1.4 2.6 
67775 Rtp4 receptor transporter protein 4 3.1 2.7 5.4 3.0 2.9 4.2 1.4 2.6 
12267 C3ar1 
complement component 3a 
receptor 1 8.0 8.0 9.4 9.3 8.0 9.3 1.4 2.5 
13032 Ctsc cathepsin C 6.5 6.6 7.5 8.3 6.6 7.9 1.4 2.5 
735268 Mir680-1 microRNA 680-1 4.4 5.8 6.7 6.2 5.1 6.4 1.3 2.5 
50778 Rgs1 
regulator of G-protein signaling 
1 4.2 4.6 6.1 5.4 4.4 5.7 1.3 2.5 
15442 Hpse heparanase 5.4 5.7 6.3 7.4 5.5 6.9 1.3 2.5 
56847 Aldh1a3 
aldehyde dehydrogenase family 
1, subfamily A3 4.6 4.0 6.2 5.0 4.3 5.6 1.3 2.5 
12045 Bcl2a1b 
B cell leukemia/lymphoma 2 
related protein A1b 7.4 7.1 8.8 8.4 7.3 8.6 1.3 2.5 
100628614 Mir5123 microRNA 5123 3.2 3.5 4.5 4.8 3.3 4.7 1.3 2.5 
104759 Pld4 
phospholipase D family, 
member 4 6.0 4.4 5.7 7.3 5.2 6.5 1.3 2.5 
73329 1700040F15Rik RIKEN cDNA 1700040F15 gene 4.4 5.6 6.5 6.1 5.0 6.3 1.3 2.5 
68738 Acss1 
acyl-CoA synthetase short-chain 
family member 1 2.7 3.4 3.8 4.9 3.1 4.4 1.3 2.5 
52855 Lair1 
leukocyte-associated Ig-like 
receptor 1 5.5 5.2 6.9 6.4 5.3 6.7 1.3 2.5 
27419 Naglu 
alpha-N-acetylglucosaminidase 
(Sanfilippo disease IIIB) 5.5 4.9 6.0 7.0 5.2 6.5 1.3 2.5 
74039 Nfam1 
Nfat activating molecule with 
ITAM motif 1 4.4 4.0 5.2 5.9 4.2 5.5 1.3 2.5 
30955 Pik3cg 
phosphoinositide-3-kinase, 
catalytic, gamma polypeptide 4.2 3.9 5.0 5.6 4.0 5.3 1.3 2.5 
170744 Tlr8 toll-like receptor 8 4.8 4.6 5.6 6.4 4.7 6.0 1.3 2.5 
210293 Dock10 dedicator of cytokinesis 10 5.9 5.7 6.5 7.7 5.8 7.1 1.3 2.5 
212937 Tifab 
TRAF-interacting protein with 
forkhead-associated domain, 
family member B 3.6 3.3 4.2 5.4 3.5 4.8 1.3 2.5 
16411 Itgax integrin alpha X 5.5 6.9 6.3 8.8 6.2 7.5 1.3 2.4 
407790 Ndufa4l2 
NADH dehydrogenase 
(ubiquinone) 1 alpha 
subcomplex, 4-like 2 3.6 6.2 6.3 6.1 4.9 6.2 1.3 2.4 
16790 Anpep 
alanyl (membrane) 
aminopeptidase 8.8 9.0 10.0 10.4 8.9 10.2 1.3 2.4 
12044 Bcl2a1a 
B cell leukemia/lymphoma 2 
related protein A1a 6.0 6.3 7.2 7.6 6.2 7.4 1.3 2.4 
18187 Nrp2 neuropilin 2 6.7 6.2 7.6 7.9 6.5 7.7 1.3 2.4 
71653 4930506M07Rik RIKEN cDNA 4930506M07 gene 6.1 5.5 6.4 7.7 5.8 7.1 1.3 2.4 
60533 Cd274 CD274 antigen 4.7 4.5 4.6 7.1 4.6 5.8 1.3 2.4 
18726 Lilra6 
leukocyte immunoglobulin-like 
receptor, subfamily A (with TM 
domain), member 6 3.7 3.8 4.8 5.2 3.7 5.0 1.3 2.4 
228026 Pdk1 
pyruvate dehydrogenase 
kinase, isoenzyme 1 3.8 4.7 5.5 5.4 4.2 5.5 1.3 2.4 
13034 Ctse cathepsin E 3.0 4.3 3.2 6.7 3.7 4.9 1.3 2.4 
15163 Hcls1 
hematopoietic cell specific Lyn 
substrate 1 6.1 5.7 7.1 7.2 5.9 7.2 1.3 2.4 
16822 Lcp2 lymphocyte cytosolic protein 2 5.3 5.3 6.2 6.9 5.3 6.5 1.3 2.4 
237542 Osbpl8 oxysterol binding protein-like 8 7.6 7.1 8.6 8.7 7.4 8.6 1.3 2.4 
12523 Cd84 CD84 antigen 6.8 7.1 7.8 8.7 7.0 8.2 1.3 2.4 
56619 Clec4e 
C-type lectin domain family 4, 
member e 5.4 3.8 5.5 6.2 4.6 5.8 1.3 2.4 
211228 Lrrc25 
leucine rich repeat containing 
25 3.9 4.3 5.0 5.7 4.1 5.3 1.3 2.4 
12508 Cd53 CD53 antigen 8.5 8.5 9.6 10.0 8.5 9.8 1.2 2.4 
83490 Pik3ap1 
phosphoinositide-3-kinase 
adaptor protein 1 5.5 5.5 6.8 6.6 5.5 6.7 1.2 2.4 
56193 Plek pleckstrin 7.7 7.6 8.6 9.3 7.7 8.9 1.2 2.4 
78591 A430104N18Rik RIKEN cDNA A430104N18 gene 4.5 3.2 4.4 5.7 3.8 5.1 1.2 2.3 
72042 Cotl1 coactosin-like 1 (Dictyostelium) 6.7 6.2 7.2 8.2 6.4 7.7 1.2 2.3 
101056121 LOC101056121 
Y-linked testis-specific protein 
1-like 4.2 4.5 5.6 5.6 4.4 5.6 1.2 2.3 
56857 Slc37a2 
solute carrier family 37 
(glycerol-3-phosphate 
transporter), member 2 5.2 4.7 6.2 6.2 5.0 6.2 1.2 2.3 
170743 Tlr7 toll-like receptor 7 4.9 4.8 5.7 6.4 4.8 6.1 1.2 2.3 
436467 Trav14-1 
T cell receptor alpha variable 
14-1 2.9 3.9 4.7 4.5 3.4 4.6 1.2 2.3 
53314 Batf 
basic leucine zipper 
transcription factor, ATF-like 3.8 3.7 4.5 5.4 3.7 4.9 1.2 2.3 
12493 Cd37 CD37 antigen 4.9 4.7 5.9 6.2 4.8 6.1 1.2 2.3 
16414 Itgb2 integrin beta 2 7.3 7.1 7.8 9.1 7.2 8.4 1.2 2.3 
56792 Stap1 
signal transducing adaptor 
family member 1 3.4 3.7 5.0 4.6 3.6 4.8 1.2 2.3 
239393 Lrp12 
low density lipoprotein-related 
protein 12 6.6 6.4 7.2 8.2 6.5 7.7 1.2 2.3 
22368 Trpv2 
transient receptor potential 
cation channel, subfamily V, 
member 2 6.1 5.6 7.0 7.1 5.8 7.0 1.2 2.3 
100504230 AU020206 expressed sequence AU020206 8.0 7.0 8.5 8.8 7.5 8.7 1.2 2.3 
212032 Hk3 hexokinase 3 3.8 4.0 5.0 5.2 3.9 5.1 1.2 2.3 
80719 Igsf6 
immunoglobulin superfamily, 
member 6 6.0 6.3 6.8 8.0 6.2 7.4 1.2 2.3 
78771 Mctp1 
multiple C2 domains, 
transmembrane 1 5.4 4.9 6.1 6.6 5.2 6.3 1.2 2.3 
20564 Slit3 slit homolog 3 (Drosophila) 6.3 5.8 7.7 6.8 6.1 7.3 1.2 2.3 
216991 Adap2 ArfGAP with dual PH domains 2 4.2 3.8 5.0 5.4 4.0 5.2 1.2 2.3 
54725 Cadm1 cell adhesion molecule 1 6.9 5.7 7.4 7.6 6.3 7.5 1.2 2.3 
18106 Cd244 
CD244 natural killer cell 
receptor 2B4 3.0 2.8 3.3 4.9 2.9 4.1 1.2 2.3 
16154 Il10ra interleukin 10 receptor, alpha 3.8 4.0 4.8 5.3 3.9 5.1 1.2 2.3 
101056060 LOC101056060 
Y-linked testis-specific protein 
1-like 4.8 5.5 6.4 6.2 5.1 6.3 1.2 2.3 
23833 Cd52 CD52 antigen 7.1 6.9 7.7 8.7 7.0 8.2 1.2 2.3 
12825 Col3a1 collagen, type III, alpha 1 5.5 5.4 7.0 6.2 5.4 6.6 1.2 2.3 
66102 Cxcl16 
chemokine (C-X-C motif) ligand 
16 6.8 6.4 7.7 7.9 6.6 7.8 1.2 2.3 
16331 Inpp5d 
inositol polyphosphate-5-
phosphatase D 5.8 5.3 6.6 6.9 5.6 6.7 1.2 2.3 
68279 Mcoln2 mucolipin 2 5.3 4.4 6.0 6.1 4.9 6.0 1.2 2.3 
109225 Ms4a7 
membrane-spanning 4-
domains, subfamily A, member 
7 8.8 8.1 9.9 9.5 8.5 9.7 1.2 2.3 
100034251 Wfdc17 
WAP four-disulfide core domain 
17 9.0 9.3 9.6 11.1 9.2 10.4 1.2 2.3 
73149 Clec4a3 
C-type lectin domain family 4, 
member a3 3.1 3.9 4.2 5.1 3.5 4.7 1.2 2.3 
16658 Mafb 
v-maf musculoaponeurotic 
fibrosarcoma oncogene family, 
protein B (avian) 4.9 4.7 5.9 6.1 4.8 6.0 1.2 2.3 
245945 Rbm47 RNA binding motif protein 47 4.1 3.9 5.0 5.3 4.0 5.1 1.2 2.3 
21938 Tnfrsf1b 
tumor necrosis factor receptor 
superfamily, member 1b 6.8 6.5 7.3 8.4 6.7 7.8 1.2 2.3 
57257 Vav3 vav 3 oncogene 3.4 3.0 4.3 4.4 3.2 4.3 1.2 2.3 
219144 Arl11 ADP-ribosylation factor-like 11 4.9 4.6 5.7 6.1 4.7 5.9 1.2 2.2 
12260 C1qb 
complement component 1, q 
subcomponent, beta 
polypeptide 8.3 8.1 9.3 9.4 8.2 9.4 1.2 2.2 
381654 C87414 expressed sequence C87414 2.3 4.2 4.3 4.6 3.3 4.4 1.2 2.2 
108101 Fermt3 
fermitin family homolog 3 
(Drosophila) 4.6 4.6 5.7 5.9 4.6 5.8 1.2 2.2 
207839 Galnt6 
UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-
acetylgalactosaminyltransferase 
6 4.9 4.5 5.4 6.3 4.7 5.9 1.2 2.2 
18826 Lcp1 lymphocyte cytosolic protein 1 7.9 7.9 8.9 9.2 7.9 9.1 1.2 2.2 
73656 Ms4a6c 
membrane-spanning 4-
domains, subfamily A, member 
6C 4.3 3.8 4.6 5.8 4.1 5.2 1.2 2.2 
22368 Trpv2 
transient receptor potential 
cation channel, subfamily V, 
member 2 6.3 6.1 7.5 7.3 6.2 7.4 1.2 2.2 
54445 Unc93b1 unc-93 homolog B1 (C. elegans) 6.6 6.2 7.3 7.8 6.4 7.6 1.2 2.2 
12721 Coro1a 
coronin, actin binding protein 
1A 5.1 5.2 6.3 6.3 5.1 6.3 1.2 2.2 
12978 Csf1r 
colony stimulating factor 1 
receptor 6.7 6.3 7.7 7.7 6.5 7.7 1.2 2.2 
20311 Cxcl5 
chemokine (C-X-C motif) ligand 
5 3.5 4.3 4.6 5.5 3.9 5.1 1.2 2.2 
13058 Cybb 
cytochrome b-245, beta 
polypeptide 7.6 7.2 7.9 9.2 7.4 8.6 1.2 2.2 
17948 Naip2 
NLR family, apoptosis inhibitory 
protein 2 5.1 4.8 5.8 6.4 5.0 6.1 1.2 2.2 
11468 Actg2 
actin, gamma 2, smooth 
muscle, enteric 8.1 7.6 9.4 8.5 7.8 9.0 1.1 2.2 
12491 Cd36 CD36 antigen 6.4 7.6 7.1 9.2 7.0 8.2 1.1 2.2 
14017 Evi2a 
ecotropic viral integration site 
2a 5.7 5.7 6.8 6.8 5.7 6.8 1.1 2.2 
23880 Fyb FYN binding protein 5.5 5.0 6.7 6.2 5.3 6.4 1.1 2.2 
70719 Hmha1 histocompatibility (minor) HA-1 4.8 4.0 5.6 5.5 4.4 5.5 1.1 2.2 
64099 Parvg parvin, gamma 3.5 3.9 3.7 5.8 3.7 4.8 1.1 2.2 
230787 Themis2 
thymocyte selection associated 
family member 2 4.5 4.3 5.1 6.0 4.4 5.5 1.1 2.2 
57425 U90926 cDNA sequence U90926 3.9 5.3 4.8 6.7 4.6 5.7 1.1 2.2 
12489 Cd33 CD33 antigen 6.0 5.7 5.7 8.2 5.8 7.0 1.1 2.2 
14191 Fgr 
Gardner-Rasheed feline 
sarcoma viral (Fgr) oncogene 
homolog 3.1 3.0 3.0 5.3 3.0 4.2 1.1 2.2 
15117 Has2 hyaluronan synthase 2 5.3 5.3 6.4 6.5 5.3 6.5 1.1 2.2 
14728 Lilrb4 
leukocyte immunoglobulin-like 
receptor, subfamily B, member 
4 9.1 9.5 10.3 10.6 9.3 10.4 1.1 2.2 
69189 Mcemp1 
mast cell expressed membrane 
protein 1 3.4 3.1 3.2 5.6 3.3 4.4 1.1 2.2 
257662 Olfr1290 olfactory receptor 1290 2.3 3.4 4.7 3.4 2.9 4.0 1.1 2.2 
241452 Dhrs9 
dehydrogenase/reductase (SDR 
family) member 9 4.0 4.2 5.2 5.3 4.1 5.3 1.1 2.2 
56743 Lat2 
linker for activation of T cells 
family, member 2 6.3 6.3 7.4 7.4 6.3 7.4 1.1 2.2 
11846 Arg1 arginase, liver 3.8 3.4 4.3 5.2 3.6 4.7 1.1 2.2 
665521 BC080696 cDNA sequence BC080696 3.5 4.0 4.7 5.0 3.7 4.8 1.1 2.2 
18830 Pltp phospholipid transfer protein 5.4 5.5 7.1 6.1 5.5 6.6 1.1 2.2 
218442 Serinc5 serine incorporator 5 5.2 5.0 5.7 6.7 5.1 6.2 1.1 2.2 
171209 Asic3 
acid-sensing (proton-gated) ion 
channel 3 3.1 3.3 5.1 3.5 3.2 4.3 1.1 2.1 
232975 Atp1a3 
ATPase, Na+/K+ transporting, 
alpha 3 polypeptide 5.6 5.3 6.0 7.2 5.5 6.6 1.1 2.1 
20305 Ccl6 chemokine (C-C motif) ligand 6 6.6 7.8 6.5 10.1 7.2 8.3 1.1 2.1 
329679 Fnip2 folliculin interacting protein 2 6.2 6.5 7.1 7.7 6.3 7.4 1.1 2.1 
83924 Gpr137b 
G protein-coupled receptor 
137B 6.4 5.8 6.8 7.6 6.1 7.2 1.1 2.1 
15950 Ifi203 interferon activated gene 203 3.4 3.1 5.0 3.7 3.2 4.3 1.1 2.1 
213391 Rassf4 
Ras association (RalGDS/AF-6) 
domain family member 4 4.6 3.4 4.9 5.3 4.0 5.1 1.1 2.1 
76408 Abcc3 
ATP-binding cassette, sub-
family C (CFTR/MRP), member 
3 5.0 4.2 5.9 5.5 4.6 5.7 1.1 2.1 
620551 LOC620551 PRAME family member 5-like 3.3 3.9 4.8 4.5 3.6 4.7 1.1 2.1 
20354 Sema4d 
sema domain, immunoglobulin 
domain (Ig), transmembrane 
domain (TM) and short 
cytoplasmic domain, 
(semaphorin) 4D 4.3 4.1 5.1 5.4 4.2 5.3 1.1 2.1 
20612 Siglec1 
sialic acid binding Ig-like lectin 
1, sialoadhesin 4.6 4.0 5.0 5.8 4.3 5.4 1.1 2.1 
65221 Slc15a3 
solute carrier family 15, 
member 3 7.3 7.4 8.1 8.8 7.3 8.4 1.1 2.1 
320148 B430306N03Rik RIKEN cDNA B430306N03 gene 4.2 4.1 4.7 5.7 4.1 5.2 1.1 2.1 
12229 Btk 
Bruton agammaglobulinemia 
tyrosine kinase 4.3 4.0 5.1 5.4 4.1 5.2 1.1 2.1 
17474 Clec4d 
C-type lectin domain family 4, 
member d 8.4 8.2 9.1 9.6 8.3 9.3 1.1 2.1 
100316820 Mir1970 microRNA 1970 3.8 3.7 4.9 4.8 3.8 4.9 1.1 2.1 
100628621 Mir3961 microRNA 3961 4.9 4.0 5.6 5.4 4.4 5.5 1.1 2.1 
20611 Ssty1 
spermiogenesis specific 
transcript on the Y 1 5.0 5.9 6.6 6.4 5.4 6.5 1.1 2.1 
226409 Zranb3 
zinc finger, RAN-binding 
domain containing 3 4.3 4.6 5.2 5.9 4.5 5.6 1.1 2.1 
232201 Arhgap25 
Rho GTPase activating protein 
25 4.8 5.4 5.7 6.7 5.1 6.2 1.1 2.1 
380732 Milr1 
mast cell immunoglobulin like 
receptor 1 4.5 4.4 5.5 5.4 4.4 5.5 1.1 2.1 
320024 Nceh1 
neutral cholesterol ester 
hydrolase 1 8.0 7.9 8.9 9.2 8.0 9.0 1.1 2.1 
14051 Eya4 
eyes absent 4 homolog 
(Drosophila) 3.3 2.8 4.4 3.8 3.1 4.1 1.1 2.1 
67731 Fbxo32 F-box protein 32 4.3 4.3 4.7 6.0 4.3 5.4 1.1 2.1 
14176 Fgf5 fibroblast growth factor 5 4.1 3.8 4.4 5.6 3.9 5.0 1.1 2.1 
237436 Gas2l3 growth arrest-specific 2 like 3 5.2 5.7 6.1 6.9 5.4 6.5 1.1 2.1 
16114 Igk-V28 
immunoglobulin kappa chain 
variable 28 (V28) 4.9 4.3 5.8 5.5 4.6 5.7 1.1 2.1 
319480 Itga11 integrin alpha 11 4.0 4.0 6.1 4.0 4.0 5.1 1.1 2.1 
320024 Nceh1 
neutral cholesterol ester 
hydrolase 1 8.0 7.9 9.0 9.1 8.0 9.1 1.1 2.1 
20846 Stat1 
signal transducer and activator 
of transcription 1 5.9 5.6 7.2 6.5 5.8 6.8 1.1 2.1 
12053 Bcl6 B cell leukemia/lymphoma 6 6.4 6.1 7.6 7.0 6.2 7.3 1.1 2.1 
12606 Cebpa 
CCAAT/enhancer binding 
protein (C/EBP), alpha 4.6 4.3 5.3 5.7 4.4 5.5 1.1 2.1 
19141 Lgmn legumain 8.4 8.3 9.3 9.4 8.3 9.4 1.1 2.1 
241633 Atp8b4 
ATPase, class I, type 8B, 
member 4 3.2 3.1 4.1 4.3 3.2 4.2 1.0 2.1 
12362 Casp1 caspase 1 5.5 5.8 6.8 6.6 5.7 6.7 1.0 2.1 
100628574 Mir28b microRNA 28b 4.0 5.3 6.1 5.2 4.6 5.7 1.0 2.1 
19200 Pstpip1 
proline-serine-threonine 
phosphatase-interacting 
protein 1 5.0 5.3 5.9 6.4 5.1 6.2 1.0 2.1 
18173 Slc11a1 
solute carrier family 11 (proton-
coupled divalent metal ion 
transporters), member 1 5.0 4.9 5.5 6.4 4.9 6.0 1.0 2.1 
18636 Cfp complement factor properdin 5.1 4.4 5.1 6.4 4.8 5.8 1.0 2.0 
14127 Fcer1g 
Fc receptor, IgE, high affinity I, 
gamma polypeptide 9.6 9.2 10.4 10.5 9.4 10.5 1.0 2.0 
16186 Il2rg 
interleukin 2 receptor, gamma 
chain 6.4 6.1 6.6 8.0 6.2 7.3 1.0 2.0 
17101 Lyst lysosomal trafficking regulator 5.5 5.6 6.3 6.9 5.6 6.6 1.0 2.0 
667742 Piezo2 
piezo-type mechanosensitive 
ion channel component 2 3.6 4.2 5.4 4.4 3.9 4.9 1.0 2.0 
19332 Rab20 
RAB20, member RAS oncogene 
family 4.4 4.1 5.4 5.2 4.3 5.3 1.0 2.0 
11980 Atp8a1 
ATPase, aminophospholipid 
transporter (APLT), class I, type 
8A, member 1 3.6 3.4 4.2 4.8 3.5 4.5 1.0 2.0 
14247 Fli1 Friend leukemia integration 1 5.4 5.4 6.2 6.7 5.4 6.4 1.0 2.0 
211401 Mtss1 metastasis suppressor 1 6.6 6.5 7.7 7.4 6.5 7.6 1.0 2.0 
17951 Naip5 
NLR family, apoptosis inhibitory 
protein 5 4.1 3.5 4.1 5.5 3.8 4.8 1.0 2.0 
241062 Pgap1 
post-GPI attachment to 
proteins 1 5.2 5.4 5.6 7.1 5.3 6.3 1.0 2.0 
19850 Rnu3a U3A small nuclear RNA 3.2 3.3 4.2 4.3 3.2 4.3 1.0 2.0 
69583 Tnfsf13 
tumor necrosis factor (ligand) 
superfamily, member 13 6.0 6.0 6.8 7.3 6.0 7.0 1.0 2.0 
20303 Ccl4 chemokine (C-C motif) ligand 4 5.7 6.1 6.9 6.9 5.9 6.9 1.0 2.0 
12483 Cd22 CD22 antigen 3.7 3.8 4.1 5.5 3.8 4.8 1.0 2.0 
234356 Csgalnact1 
chondroitin sulfate N-
acetylgalactosaminyltransferase 
1 3.5 3.4 5.2 3.7 3.5 4.5 1.0 2.0 
100041034 LOC100041034 Sp110 nuclear body protein-like 5.8 5.3 6.4 6.7 5.5 6.5 1.0 2.0 
320139 Ptpn7 
protein tyrosine phosphatase, 
non-receptor type 7 4.2 4.1 5.1 5.3 4.2 5.2 1.0 2.0 
57319 Smpdl3a 
sphingomyelin 
phosphodiesterase, acid-like 3A 6.7 6.4 7.3 7.9 6.6 7.6 1.0 2.0 
652925 Tmem243 
transmembrane protein 243, 
mitochondrial 3.8 4.2 4.8 5.3 4.0 5.0 1.0 2.0 
12262 C1qc 
complement component 1, q 
subcomponent, C chain 7.1 7.2 8.1 8.1 7.1 8.1 1.0 2.0 
101056308 LOC101056308 
Y-linked testis-specific protein 
1-like 3.5 3.9 4.9 4.5 3.7 4.7 1.0 2.0 
140795 P2ry14 
purinergic receptor P2Y, G-
protein coupled, 14 3.2 3.7 3.6 5.3 3.5 4.5 1.0 2.0 
11835 Ar androgen receptor 5.1 4.9 3.8 4.1 5.0 4.0 -1.0 -2.0 
19716 Bex1 brain expressed gene 1 5.7 6.4 3.2 6.9 6.1 5.1 -1.0 -2.0 
241520 Fam171b 
family with sequence similarity 
171, member B 4.3 4.8 3.5 3.6 4.5 3.5 -1.0 -2.0 
18481 Pak3 
p21 protein (Cdc42/Rac)-
activated kinase 3 4.8 4.7 3.8 3.7 4.7 3.7 -1.0 -2.0 
76969 Chst1 
carbohydrate (keratan sulfate 
Gal-6) sulfotransferase 1 4.6 4.6 3.9 3.2 4.6 3.6 -1.0 -2.0 
71785 Pdgfd 
platelet-derived growth factor, 
D polypeptide 6.6 5.9 5.6 4.8 6.2 5.2 -1.0 -2.0 
20289 Scx scleraxis 3.4 4.8 2.8 3.3 4.1 3.1 -1.0 -2.0 
21873 Tjp2 tight junction protein 2 6.6 6.2 5.3 5.4 6.4 5.4 -1.0 -2.0 
217310 Hid1 HID1 domain containing 4.7 5.0 3.7 3.9 4.8 3.8 -1.0 -2.0 
100604 Lrrc8c 
leucine rich repeat containing 8 
family, member C 8.2 8.1 6.6 7.7 8.2 7.1 -1.0 -2.0 
14013 Mecom MDS1 and EVI1 complex locus 4.1 4.1 3.1 3.0 4.1 3.1 -1.0 -2.0 
235505 Cd109 CD109 antigen 7.0 8.2 6.4 6.7 7.6 6.6 -1.0 -2.1 
12583 Cdo1 
cysteine dioxygenase 1, 
cytosolic 7.9 8.6 7.1 7.3 8.2 7.2 -1.0 -2.1 
13874 Ereg epiregulin 8.7 8.3 7.2 7.8 8.5 7.5 -1.0 -2.1 
22762 Zfpm2 zinc finger protein, multitype 2 5.7 5.4 4.7 4.3 5.5 4.5 -1.0 -2.1 
18214 Ddr2 
discoidin domain receptor 
family, member 2 7.5 7.4 6.9 6.0 7.5 6.4 -1.1 -2.1 
74754 Dhcr24 
24-dehydrocholesterol 
reductase 7.4 7.5 6.7 6.1 7.5 6.4 -1.1 -2.1 
66203 Lce1m late cornified envelope 1M 5.3 4.6 3.9 3.9 4.9 3.9 -1.1 -2.1 
19223 Ptgis 
prostaglandin I2 (prostacyclin) 
synthase 7.5 8.2 6.7 6.9 7.8 6.8 -1.1 -2.1 
216363 Rab3ip RAB3A interacting protein 7.4 7.5 6.6 6.1 7.4 6.4 -1.1 -2.1 
24052 Sgcd 
sarcoglycan, delta (dystrophin-
associated glycoprotein) 5.7 5.7 4.5 4.8 5.7 4.7 -1.1 -2.1 
20983 Syt4 synaptotagmin IV 5.9 3.3 3.5 3.5 4.6 3.5 -1.1 -2.1 
11752 Anxa8 annexin A8 4.6 4.6 3.7 3.4 4.6 3.6 -1.1 -2.1 
14457 Gas7 growth arrest specific 7 6.1 5.8 4.4 5.4 5.9 4.9 -1.1 -2.1 
69884 2010300F17Rik RIKEN cDNA 2010300F17 gene 5.8 4.3 4.0 3.9 5.0 4.0 -1.1 -2.1 
320692 9430037G07Rik RIKEN cDNA 9430037G07 gene 5.4 3.9 3.5 3.6 4.6 3.6 -1.1 -2.1 
20315 Cxcl12 
chemokine (C-X-C motif) ligand 
12 9.1 10.1 8.6 8.5 9.6 8.5 -1.1 -2.1 
207683 Igsf11 
immunoglobulin superfamily, 
member 11 6.8 6.6 5.0 6.3 6.7 5.6 -1.1 -2.1 
107065 Lrrtm2 
leucine rich repeat 
transmembrane neuronal 2 4.2 4.6 3.2 3.5 4.4 3.3 -1.1 -2.1 
68458 Ppp1r14a 
protein phosphatase 1, 
regulatory (inhibitor) subunit 
14A 4.6 3.4 3.2 2.8 4.0 3.0 -1.1 -2.1 
240725 Sulf1 sulfatase 1 9.3 9.5 8.7 8.0 9.4 8.4 -1.1 -2.1 
69953 2810025M15Rik RIKEN cDNA 2810025M15 gene 7.2 8.0 6.4 6.7 7.6 6.5 -1.1 -2.1 
68567 Cgref1 
cell growth regulator with EF 
hand domain 1 6.3 6.0 4.9 5.3 6.2 5.1 -1.1 -2.1 
15551 Htr1b 
5-hydroxytryptamine 
(serotonin) receptor 1B 6.2 5.6 4.7 5.0 5.9 4.8 -1.1 -2.1 
381493 S100a7a 
S100 calcium binding protein 
A7A 6.1 4.9 4.1 4.8 5.5 4.4 -1.1 -2.1 
56496 Tspan6 tetraspanin 6 8.3 7.6 7.1 6.6 7.9 6.8 -1.1 -2.1 
70892 Ttll7 
tubulin tyrosine ligase-like 
family, member 7 5.5 6.1 4.8 4.7 5.8 4.7 -1.1 -2.1 
14266 Aff2 AF4/FMR2 family, member 2 5.5 5.2 4.7 3.8 5.4 4.3 -1.1 -2.1 
104943 Fam110c 
family with sequence similarity 
110, member C 4.6 4.2 3.3 3.3 4.4 3.3 -1.1 -2.1 
14205 Figf c-fos induced growth factor 6.3 7.3 6.6 4.9 6.8 5.8 -1.1 -2.1 
20378 Frzb frizzled-related protein 6.6 7.7 6.4 5.6 7.1 6.0 -1.1 -2.1 
16447 Ivl involucrin 6.5 4.3 4.0 4.6 5.4 4.3 -1.1 -2.1 
21956 Tnnt2 troponin T2, cardiac 5.7 5.8 4.3 5.0 5.8 4.7 -1.1 -2.1 
12269 C4bp 
complement component 4 
binding protein 4.9 4.8 4.1 3.4 4.9 3.8 -1.1 -2.1 
12389 Cav1 caveolin 1, caveolae protein 8.1 7.7 6.6 6.9 7.9 6.8 -1.1 -2.1 
73379 Dcbld2 
discoidin, CUB and LCCL domain 
containing 2 7.4 6.9 6.5 5.6 7.1 6.0 -1.1 -2.1 
67350 1700084E18Rik RIKEN cDNA 1700084E18 gene 4.8 3.9 3.1 3.4 4.3 3.2 -1.1 -2.2 
66175 Mustn1 
musculoskeletal, embryonic 
nuclear protein 1 9.8 8.6 8.7 7.5 9.2 8.1 -1.1 -2.2 
269233 Fam171a1 
family with sequence similarity 
171, member A1 6.3 6.6 5.1 5.6 6.4 5.3 -1.1 -2.2 
329628 Fat4 
FAT tumor suppressor homolog 
4 (Drosophila) 5.2 5.2 4.2 4.1 5.2 4.1 -1.1 -2.2 
77446 Heg1 HEG homolog 1 (zebrafish) 7.7 8.2 7.4 6.3 7.9 6.8 -1.1 -2.2 
100503380 Snhg4 
small nucleolar RNA host gene 
4 4.7 4.2 3.1 3.4 4.4 3.3 -1.1 -2.2 
23876 Fbln5 fibulin 5 8.4 8.9 8.2 6.8 8.6 7.5 -1.1 -2.2 
16008 Igfbp2 
insulin-like growth factor 
binding protein 2 6.5 7.8 6.7 5.4 7.2 6.1 -1.1 -2.2 
233726 Ipo7 importin 7 7.9 7.4 6.5 6.5 7.6 6.5 -1.1 -2.2 
13642 Efnb2 ephrin B2 7.8 7.7 6.6 6.7 7.8 6.6 -1.1 -2.2 
67374 Jam2 junction adhesion molecule 2 8.8 9.2 7.8 7.9 9.0 7.9 -1.1 -2.2 
68404 Nrn1 neuritin 1 7.1 7.6 5.4 7.0 7.4 6.2 -1.1 -2.2 
71720 Osbpl3 oxysterol binding protein-like 3 4.8 5.0 3.4 4.1 4.9 3.7 -1.1 -2.2 
19243 Ptp4a1 
protein tyrosine phosphatase 
4a1 6.4 5.8 4.6 5.4 6.1 5.0 -1.1 -2.2 
72780 Rspo3 
R-spondin 3 homolog (Xenopus 
laevis) 6.2 6.4 6.0 4.4 6.3 5.2 -1.1 -2.2 
217410 Trib2 tribbles homolog 2 (Drosophila) 5.9 6.3 5.3 4.6 6.1 4.9 -1.1 -2.2 
12064 Bdnf 
brain derived neurotrophic 
factor 5.6 5.2 4.5 4.0 5.4 4.3 -1.2 -2.2 
14677 Gnai1 
guanine nucleotide binding 
protein (G protein), alpha 
inhibiting 1 6.3 7.0 5.6 5.5 6.7 5.5 -1.2 -2.2 
22160 Twist1 
twist basic helix-loop-helix 
transcription factor 1 6.1 6.5 5.3 5.0 6.3 5.1 -1.2 -2.2 
73720 Cst6 cystatin E/M 5.4 5.3 4.3 4.1 5.3 4.2 -1.2 -2.2 
319146 Ifnz interferon zeta 5.2 4.5 3.8 3.7 4.9 3.7 -1.2 -2.2 
23959 Nt5e 5' nucleotidase, ecto 4.7 4.3 3.1 3.5 4.5 3.3 -1.2 -2.3 
19272 Ptprk 
protein tyrosine phosphatase, 
receptor type, K 7.0 6.9 5.6 6.0 7.0 5.8 -1.2 -2.3 
20197 S100a3 
S100 calcium binding protein 
A3 5.3 5.1 3.9 4.1 5.2 4.0 -1.2 -2.3 
100217453 Snord16a 
small nucleolar RNA, C/D box 
16A 7.0 6.5 5.3 5.8 6.7 5.6 -1.2 -2.3 
11421 Ace 
angiotensin I converting 
enzyme (peptidyl-dipeptidase 
A) 1 3.4 4.8 2.9 2.9 4.1 2.9 -1.2 -2.3 
170757 Eltd1 
EGF, latrophilin seven 
transmembrane domain 
containing 1 5.1 3.6 3.1 3.2 4.4 3.2 -1.2 -2.3 
53614 Reck 
reversion-inducing-cysteine-
rich protein with kazal motifs 6.9 7.4 6.1 5.8 7.2 6.0 -1.2 -2.3 
58994 Smpd3 
sphingomyelin 
phosphodiesterase 3, neutral 5.4 4.4 3.8 3.7 4.9 3.7 -1.2 -2.3 
13797 Emx2 empty spiracles homeobox 2 5.2 4.0 3.7 3.1 4.6 3.4 -1.2 -2.3 
16773 Lama2 laminin, alpha 2 6.2 6.3 5.0 5.1 6.3 5.1 -1.2 -2.3 
17386 Mmp13 matrix metallopeptidase 13 8.3 9.1 6.8 8.1 8.7 7.5 -1.2 -2.3 
22329 Vcam1 
vascular cell adhesion molecule 
1 8.2 8.3 7.2 6.9 8.2 7.0 -1.2 -2.3 
217887 BC022687 cDNA sequence BC022687 6.7 6.6 5.4 5.4 6.6 5.4 -1.2 -2.3 
19224 Ptgs1 
prostaglandin-endoperoxide 
synthase 1 7.1 7.8 5.9 6.5 7.4 6.2 -1.2 -2.3 
14611 Gja3 gap junction protein, alpha 3 5.1 3.5 3.2 2.8 4.3 3.0 -1.2 -2.3 
13876 Erg 
avian erythroblastosis virus E-
26 (v-ets) oncogene related 4.6 4.4 3.2 3.3 4.5 3.3 -1.2 -2.3 
16669 Krt19 keratin 19 4.5 4.6 3.4 3.3 4.6 3.3 -1.2 -2.3 
216459 Myl6b myosin, light polypeptide 6B 5.6 5.5 4.5 4.2 5.6 4.3 -1.2 -2.3 
18788 Serpinb2 
serine (or cysteine) peptidase 
inhibitor, clade B, member 2 7.8 6.1 4.1 7.3 6.9 5.7 -1.2 -2.3 
20042 Rps12 ribosomal protein S12 4.9 4.6 3.3 3.7 4.7 3.5 -1.2 -2.4 
97848 Serpinb6c 
serine (or cysteine) peptidase 
inhibitor, clade B, member 6c 7.1 5.7 5.7 4.5 6.4 5.1 -1.3 -2.4 
23967 Osr1 
odd-skipped related 1 
(Drosophila) 7.9 9.0 7.6 6.8 8.5 7.2 -1.3 -2.4 
16367 Irs1 insulin receptor substrate 1 6.2 5.7 4.8 4.6 6.0 4.7 -1.3 -2.4 
13395 Dlx5 distal-less homeobox 5 3.0 5.2 3.0 2.6 4.1 2.8 -1.3 -2.4 
110454 Ly6a 
lymphocyte antigen 6 complex, 
locus A 8.1 10.1 8.1 7.6 9.1 7.9 -1.3 -2.4 
73904 4833412C05Rik RIKEN cDNA 4833412C05 gene 5.9 4.9 3.9 4.3 5.4 4.1 -1.3 -2.4 
14461 Gata2 GATA binding protein 2 4.7 4.3 3.3 3.1 4.5 3.2 -1.3 -2.5 
279653 Pcdh19 protocadherin 19 7.3 6.7 5.9 5.6 7.0 5.7 -1.3 -2.5 
109294 Prex2 
phosphatidylinositol-3,4,5-
trisphosphate-dependent Rac 
exchange factor 2 5.5 5.5 4.3 4.1 5.5 4.2 -1.3 -2.5 
229672 Bcl2l15 BCLl2-like 15 5.4 4.9 3.1 4.7 5.2 3.9 -1.3 -2.5 
216616 Efemp1 
epidermal growth factor-
containing fibulin-like 
extracellular matrix protein 1 7.9 9.6 7.8 7.1 8.8 7.5 -1.3 -2.5 
11668 Aldh1a1 
aldehyde dehydrogenase family 
1, subfamily A1 7.8 7.0 6.6 5.5 7.4 6.1 -1.3 -2.5 
407828 BC023969 cDNA sequence BC023969 3.8 5.7 3.3 3.5 4.7 3.4 -1.3 -2.5 
216831 Arhgap44 
Rho GTPase activating protein 
44 6.4 6.4 5.3 4.9 6.4 5.1 -1.3 -2.5 
211323 Nrg1 neuregulin 1 6.6 5.6 4.8 4.7 6.1 4.8 -1.3 -2.5 
16398 Itga2 integrin alpha 2 6.5 6.7 4.6 5.8 6.6 5.2 -1.4 -2.6 
433619 Kprp 
keratinocyte expressed, 
proline-rich 7.2 5.5 5.0 4.8 6.3 4.9 -1.4 -2.7 
27273 Pdk4 
pyruvate dehydrogenase 
kinase, isoenzyme 4 7.5 6.6 5.5 5.8 7.1 5.6 -1.4 -2.7 
94242 Tinagl1 
tubulointerstitial nephritis 
antigen-like 1 6.7 7.3 5.5 5.7 7.0 5.6 -1.4 -2.7 
14600 Ghr growth hormone receptor 7.7 7.4 6.3 6.1 7.6 6.2 -1.4 -2.7 
73738 Haus7 
HAUS augmin-like complex, 
subunit 7 5.6 6.4 4.7 4.5 6.0 4.6 -1.4 -2.7 
15483 Hsd11b1 
hydroxysteroid 11-beta 
dehydrogenase 1 5.3 7.2 5.0 4.6 6.2 4.8 -1.4 -2.7 
29818 Hspb7 
heat shock protein family, 
member 7 (cardiovascular) 7.6 8.1 6.4 6.4 7.9 6.4 -1.4 -2.7 
11731 Ang2 
angiogenin, ribonuclease A 
family, member 2 7.4 7.7 5.9 6.2 7.5 6.0 -1.5 -2.8 
12161 Bmp6 bone morphogenetic protein 6 5.0 4.8 3.6 3.2 4.9 3.4 -1.5 -2.8 
73173 Pcdh18 protocadherin 18 6.8 6.1 5.2 4.8 6.4 5.0 -1.5 -2.8 
223881 Rnd1 Rho family GTPase 1 5.8 6.1 4.5 4.5 6.0 4.5 -1.5 -2.8 
110058 Syt17 synaptotagmin XVII 7.0 7.0 5.2 5.9 7.0 5.5 -1.5 -2.8 
54195 Gucy1b3 
guanylate cyclase 1, soluble, 
beta 3 6.2 5.3 4.1 4.4 5.8 4.3 -1.5 -2.8 
19124 Procr protein C receptor, endothelial 8.0 6.8 5.8 6.1 7.4 5.9 -1.5 -2.8 
654795 Sdr39u1 
short chain 
dehydrogenase/reductase 
family 39U, member 1 7.1 4.8 4.1 4.9 6.0 4.5 -1.5 -2.8 
56429 Dpt dermatopontin 6.9 5.8 4.4 5.3 6.4 4.8 -1.5 -2.8 
224792 Gpr116 G protein-coupled receptor 116 4.9 4.3 3.0 3.1 4.6 3.1 -1.5 -2.9 
26415 Mapk13 
mitogen-activated protein 
kinase 13 6.6 6.6 4.8 5.4 6.6 5.1 -1.5 -2.9 
18383 Tnfrsf11b 
tumor necrosis factor receptor 
superfamily, member 11b 
(osteoprotegerin) 7.6 7.9 6.5 6.0 7.8 6.2 -1.5 -2.9 
13024 Ctla2a 
cytotoxic T lymphocyte-
associated protein 2 alpha 9.5 8.7 7.9 7.2 9.1 7.6 -1.5 -2.9 
76400 Pbp2 
phosphatidylethanolamine 
binding protein 2 5.7 4.6 4.0 3.2 5.1 3.6 -1.5 -2.9 
228765 Sdcbp2 
syndecan binding protein 
(syntenin) 2 7.0 5.4 4.7 4.6 6.2 4.7 -1.5 -2.9 
20706 Serpinb9b 
serine (or cysteine) peptidase 
inhibitor, clade B, member 9b 9.4 9.1 8.0 7.4 9.2 7.7 -1.5 -2.9 
12484 Cd24a CD24a antigen 9.4 8.5 6.3 8.6 9.0 7.4 -1.6 -3.0 
14858 Gsta2 
glutathione S-transferase, alpha 
2 (Yc2) 5.7 6.1 4.4 4.2 5.9 4.3 -1.6 -3.0 
20682 Sox9 
SRY (sex determining region Y)-
box 9 5.1 6.6 3.9 4.6 5.8 4.2 -1.6 -3.0 
22634 Plagl1 
pleiomorphic adenoma gene-
like 1 5.6 6.3 3.5 5.2 6.0 4.4 -1.6 -3.0 
12349 Car2 carbonic anhydrase 2 6.1 5.2 3.8 4.3 5.7 4.0 -1.6 -3.1 
268977 Ltbp1 
latent transforming growth 
factor beta binding protein 1 6.7 7.4 5.2 5.6 7.0 5.4 -1.6 -3.1 
13614 Edn1 endothelin 1 8.8 7.8 6.6 6.8 8.3 6.7 -1.7 -3.2 
13640 Efna5 ephrin A5 6.2 6.6 4.3 5.1 6.4 4.7 -1.7 -3.2 
11459 Acta1 actin, alpha 1, skeletal muscle 8.8 7.7 5.6 7.6 8.2 6.6 -1.7 -3.2 
232431 Gprc5a 
G protein-coupled receptor, 
family C, group 5, member A 4.6 4.8 2.6 3.4 4.7 3.0 -1.7 -3.2 
68178 Cgnl1 cingulin-like 1 7.7 7.3 5.6 6.1 7.5 5.8 -1.7 -3.2 
68052 Rps13 ribosomal protein S13 4.3 4.5 2.6 2.8 4.4 2.7 -1.7 -3.2 
11435 Chrna1 
cholinergic receptor, nicotinic, 
alpha polypeptide 1 (muscle) 3.7 5.1 2.7 2.7 4.4 2.7 -1.7 -3.3 
14368 Fzd6 frizzled homolog 6 (Drosophila) 5.8 4.7 3.4 3.6 5.2 3.5 -1.7 -3.3 
16400 Itga3 integrin alpha 3 5.4 5.1 3.3 3.7 5.2 3.5 -1.7 -3.3 
64058 Perp PERP, TP53 apoptosis effector 6.2 5.0 3.9 3.9 5.6 3.9 -1.7 -3.3 
17389 Mmp16 matrix metallopeptidase 16 4.7 5.1 3.3 3.1 4.9 3.2 -1.7 -3.3 
320092 E030003E18Rik RIKEN cDNA E030003E18 gene 5.9 5.1 4.5 3.1 5.5 3.8 -1.8 -3.4 
224093 Fam43a 
family with sequence similarity 
43, member A 6.3 6.6 5.2 4.2 6.5 4.7 -1.8 -3.4 
20324 Sdpr serum deprivation response 8.9 9.5 7.5 7.4 9.2 7.4 -1.8 -3.4 
13717 Eln elastin 5.1 6.6 4.0 4.1 5.8 4.0 -1.8 -3.5 
67718 Lce1h late cornified envelope 1H 7.7 3.3 3.7 3.7 5.5 3.7 -1.8 -3.5 
20708 Serpinb6b 
serine (or cysteine) peptidase 
inhibitor, clade B, member 6b 8.3 7.9 6.7 5.9 8.1 6.3 -1.8 -3.5 
14725 Lrp2 
low density lipoprotein 
receptor-related protein 2 5.2 4.1 2.8 2.9 4.7 2.8 -1.8 -3.5 
16891 Lipg lipase, endothelial 5.0 4.6 2.7 3.2 4.8 3.0 -1.8 -3.6 
67828 Lce1f late cornified envelope 1F 7.2 3.1 3.3 3.2 5.1 3.3 -1.9 -3.6 
18104 Nqo1 
NAD(P)H dehydrogenase, 
quinone 1 7.3 7.4 5.0 5.9 7.3 5.5 -1.9 -3.7 
105450 Mmrn2 multimerin 2 6.3 5.3 3.7 4.1 5.8 3.9 -1.9 -3.8 
71690 Esm1 
endothelial cell-specific 
molecule 1 8.1 8.2 5.9 6.5 8.2 6.2 -1.9 -3.8 
94253 Hecw1 
HECT, C2 and WW domain 
containing E3 ubiquitin protein 
ligase 1 6.1 4.9 3.8 3.2 5.5 3.5 -2.0 -4.1 
105349 Akr1c18 
aldo-keto reductase family 1, 
member C18 5.6 8.0 4.0 5.3 6.8 4.7 -2.1 -4.3 
101772 Ano1 
anoctamin 1, calcium activated 
chloride channel 5.1 4.7 2.7 2.8 4.9 2.7 -2.1 -4.4 
21892 Tll1 tolloid-like 8.4 8.0 5.6 6.5 8.2 6.1 -2.1 -4.4 
69325 1700012B09Rik RIKEN cDNA 1700012B09 gene 5.8 6.9 3.7 4.5 6.4 4.1 -2.3 -4.9 
12159 Bmp4 bone morphogenetic protein 4 7.5 7.8 6.6 4.1 7.7 5.4 -2.3 -5.1 
319154 Hist2h3b histone cluster 2, H3b 6.2 4.5 2.5 3.5 5.4 3.0 -2.4 -5.2 
22268 Upk1b uroplakin 1B 9.2 5.8 4.3 5.9 7.5 5.1 -2.4 -5.2 
12490 Cd34 CD34 antigen 7.0 5.8 3.5 4.5 6.4 4.0 -2.4 -5.3 
114301 Palmd palmdelphin 6.1 5.2 3.3 3.1 5.6 3.2 -2.4 -5.4 
20344 Selp selectin, platelet 6.3 6.5 3.9 4.1 6.4 4.0 -2.5 -5.5 
59308 Emcn endomucin 9.3 8.1 6.0 6.5 8.7 6.2 -2.5 -5.6 
18613 Pecam1 
platelet/endothelial cell 
adhesion molecule 1 6.7 6.3 3.9 4.1 6.5 4.0 -2.5 -5.6 
12562 Cdh5 cadherin 5 8.7 7.0 5.0 5.7 7.8 5.3 -2.5 -5.7 
18812 Prl2c3 
prolactin family 2, subfamily c, 
member 3 9.5 9.0 6.4 6.6 9.2 6.5 -2.7 -6.6 
18812 Prl2c3 
prolactin family 2, subfamily c, 
member 3 9.3 9.0 6.2 6.6 9.1 6.4 -2.7 -6.7 
223272 Itgbl1 integrin, beta-like 1 7.6 7.7 4.5 5.2 7.6 4.9 -2.8 -6.7 
76294 Asb5 
ankyrin repeat and SOCs box-
containing 5 7.8 6.9 3.7 5.4 7.3 4.6 -2.8 -6.8 
240873 Tnfsf18 
tumor necrosis factor (ligand) 
superfamily, member 18 9.1 7.0 4.5 6.0 8.0 5.2 -2.8 -7.1 
20753 Sprr1a small proline-rich protein 1A 8.6 9.6 5.4 7.1 9.1 6.2 -2.8 -7.2 
19263 Ptprb 
protein tyrosine phosphatase, 
receptor type, B 6.5 6.4 3.7 3.5 6.4 3.6 -2.9 -7.4 
228576 Mall 
mal, T cell differentiation 
protein-like 8.2 5.7 4.4 3.6 7.0 4.0 -3.0 -7.9 
72381 2210409E12Rik 
transcription elongation factor 
B (SIII), polypeptide 2 
pseudogene 6.4 6.0 4.0 2.3 6.2 3.2 -3.0 -8.1 
12319 Car8 carbonic anhydrase 8 7.3 7.2 4.4 4.0 7.2 4.2 -3.0 -8.1 
68632 Myct1 myc target 1 7.4 6.7 3.9 4.2 7.1 4.0 -3.0 -8.1 
74175 Crct1 cysteine-rich C-terminal 1 6.6 6.4 3.1 3.8 6.5 3.4 -3.1 -8.3 
224796 Clic5 chloride intracellular channel 5 6.4 6.9 2.9 3.1 6.7 3.0 -3.7 -12.6 
Figure S1. Arterial trees dissected from Cre(-), SM22α-Cre(+), and aP2-Cre(+) MMP14F/FApoe–/– 
male and female mice after a 12-week Western diet.  
 
Figure S2. Gene expression of Acta2(α-SMA), Cre enzyme, MT1-MMP (MMP14), MMP2, MMP8, 
MMP9, MMP13, and MT2-MMP (MMP15) in primary VSMCs isolated from Cre(-) and SM22α-Cre(+) 
MMP14F/FApoe–/– mice. Almost complete suppression of MT1-MMP expression in primary VSMCs 
was confirmed coupled with SM22-dependent Cre expression. Expression of other MMPs was not 
affected. *** P<0.001  
 
 
 
